false Q2 0000718937 --01-01 Large Accelerated Filer P3Y P2Y P1Y1M6D P2Y2M12D P2Y3M18D P5Y8M19D P5Y8M1D P5Y8M19D P5Y8M1D 0000718937 2020-01-04 2020-07-03 xbrli:shares 0000718937 2020-07-31 iso4217:USD 0000718937 2020-07-03 0000718937 2020-01-03 iso4217:USD xbrli:shares 0000718937 2020-04-04 2020-07-03 0000718937 2019-03-30 2019-06-28 0000718937 2018-12-29 2019-06-28 0000718937 us-gaap:CommonStockMember 2020-04-03 0000718937 us-gaap:AdditionalPaidInCapitalMember 2020-04-03 0000718937 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-03 0000718937 us-gaap:RetainedEarningsMember 2020-04-03 0000718937 2020-04-03 0000718937 us-gaap:RetainedEarningsMember 2020-04-04 2020-07-03 0000718937 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-04 2020-07-03 0000718937 us-gaap:CommonStockMember 2020-04-04 2020-07-03 0000718937 us-gaap:AdditionalPaidInCapitalMember 2020-04-04 2020-07-03 0000718937 us-gaap:CommonStockMember 2020-07-03 0000718937 us-gaap:AdditionalPaidInCapitalMember 2020-07-03 0000718937 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-03 0000718937 us-gaap:RetainedEarningsMember 2020-07-03 0000718937 us-gaap:CommonStockMember 2019-03-29 0000718937 us-gaap:AdditionalPaidInCapitalMember 2019-03-29 0000718937 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-29 0000718937 us-gaap:RetainedEarningsMember 2019-03-29 0000718937 2019-03-29 0000718937 us-gaap:RetainedEarningsMember 2019-03-30 2019-06-28 0000718937 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-30 2019-06-28 0000718937 us-gaap:CommonStockMember 2019-03-30 2019-06-28 0000718937 us-gaap:AdditionalPaidInCapitalMember 2019-03-30 2019-06-28 0000718937 us-gaap:CommonStockMember 2019-06-28 0000718937 us-gaap:AdditionalPaidInCapitalMember 2019-06-28 0000718937 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-28 0000718937 us-gaap:RetainedEarningsMember 2019-06-28 0000718937 2019-06-28 0000718937 us-gaap:CommonStockMember 2020-01-03 0000718937 us-gaap:AdditionalPaidInCapitalMember 2020-01-03 0000718937 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-03 0000718937 us-gaap:RetainedEarningsMember 2020-01-03 0000718937 us-gaap:RetainedEarningsMember 2020-01-04 2020-07-03 0000718937 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-04 2020-07-03 0000718937 us-gaap:CommonStockMember 2020-01-04 2020-07-03 0000718937 us-gaap:AdditionalPaidInCapitalMember 2020-01-04 2020-07-03 0000718937 us-gaap:CommonStockMember 2018-12-28 0000718937 us-gaap:AdditionalPaidInCapitalMember 2018-12-28 0000718937 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-28 0000718937 us-gaap:RetainedEarningsMember 2018-12-28 0000718937 2018-12-28 0000718937 us-gaap:RetainedEarningsMember 2018-12-29 2019-06-28 0000718937 us-gaap:AccountingStandardsUpdate201602Member us-gaap:RetainedEarningsMember srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember 2018-12-28 0000718937 us-gaap:AccountingStandardsUpdate201602Member srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember 2018-12-28 0000718937 us-gaap:AccountingStandardsUpdate201807Member us-gaap:AdditionalPaidInCapitalMember srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember 2018-12-28 0000718937 us-gaap:AccountingStandardsUpdate201807Member us-gaap:RetainedEarningsMember srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember 2018-12-28 0000718937 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-29 2019-06-28 0000718937 us-gaap:CommonStockMember 2018-12-29 2019-06-28 0000718937 us-gaap:AdditionalPaidInCapitalMember 2018-12-29 2019-06-28 xbrli:pure 0000718937 us-gaap:SupplierConcentrationRiskMember staa:ConsolidatedAccountsPayableMember srt:MaximumMember 2020-01-04 2020-07-03 0000718937 us-gaap:SupplierConcentrationRiskMember staa:ConsolidatedAccountsPayableMember srt:MaximumMember 2018-12-29 2020-01-03 0000718937 us-gaap:SupplierConcentrationRiskMember staa:ConsolidatedPurchasesMember srt:MaximumMember 2020-04-04 2020-07-03 0000718937 us-gaap:SupplierConcentrationRiskMember staa:ConsolidatedPurchasesMember srt:MaximumMember 2020-01-04 2020-07-03 0000718937 staa:PatentsAndLicensesMember 2020-07-03 0000718937 staa:PatentsAndLicensesMember 2020-01-03 iso4217:JPY 0000718937 staa:MizuhoBankMember 2020-07-03 0000718937 staa:MizuhoBankMember 2020-01-04 2020-07-03 0000718937 staa:MizuhoBankMember 2020-01-03 iso4217:CHF 0000718937 staa:CreditSuisseBankMember 2013-09-30 0000718937 staa:CreditSuisseBankMember 2020-07-03 0000718937 staa:CreditSuisseBankMember 2020-01-03 0000718937 staa:CreditSuisseBankMember 2020-01-04 2020-07-03 0000718937 srt:MinimumMember 2020-07-03 0000718937 srt:MaximumMember 2020-07-03 0000718937 us-gaap:MachineryAndEquipmentMember 2020-07-03 0000718937 us-gaap:MachineryAndEquipmentMember 2020-01-03 0000718937 us-gaap:ComputerEquipmentMember 2020-07-03 0000718937 us-gaap:ComputerEquipmentMember 2020-01-03 0000718937 us-gaap:FurnitureAndFixturesMember 2020-01-03 0000718937 us-gaap:LeaseholdImprovementsMember 2020-01-03 0000718937 us-gaap:RealEstateMember 2020-07-03 0000718937 us-gaap:RealEstateMember 2020-01-03 0000718937 us-gaap:DomesticCountryMember 2020-01-04 2020-07-03 0000718937 us-gaap:StateAndLocalJurisdictionMember 2020-01-04 2020-07-03 0000718937 country:US 2020-07-03 0000718937 us-gaap:DomesticCountryMember 2020-07-03 0000718937 us-gaap:StateAndLocalJurisdictionMember 2020-07-03 0000718937 staa:SwissPensionPlanMember 2020-04-04 2020-07-03 0000718937 staa:SwissPensionPlanMember 2019-03-30 2019-06-28 0000718937 staa:SwissPensionPlanMember 2020-01-04 2020-07-03 0000718937 staa:SwissPensionPlanMember 2018-12-29 2019-06-28 0000718937 us-gaap:EmployeeStockOptionMember 2020-04-04 2020-07-03 0000718937 us-gaap:EmployeeStockOptionMember 2019-03-30 2019-06-28 0000718937 us-gaap:EmployeeStockOptionMember 2020-01-04 2020-07-03 0000718937 us-gaap:EmployeeStockOptionMember 2018-12-29 2019-06-28 0000718937 us-gaap:RestrictedStockMember 2020-04-04 2020-07-03 0000718937 us-gaap:RestrictedStockMember 2019-03-30 2019-06-28 0000718937 us-gaap:RestrictedStockMember 2020-01-04 2020-07-03 0000718937 us-gaap:RestrictedStockMember 2018-12-29 2019-06-28 0000718937 us-gaap:RestrictedStockUnitsRSUMember 2020-04-04 2020-07-03 0000718937 us-gaap:RestrictedStockUnitsRSUMember 2019-03-30 2019-06-28 0000718937 us-gaap:RestrictedStockUnitsRSUMember 2020-01-04 2020-07-03 0000718937 us-gaap:RestrictedStockUnitsRSUMember 2018-12-29 2019-06-28 0000718937 staa:NonEmployeeStockOptionsMember 2020-04-04 2020-07-03 0000718937 staa:NonEmployeeStockOptionsMember 2019-03-30 2019-06-28 0000718937 staa:NonEmployeeStockOptionsMember 2020-01-04 2020-07-03 0000718937 staa:NonEmployeeStockOptionsMember 2018-12-29 2019-06-28 0000718937 us-gaap:CostOfSalesMember 2020-04-04 2020-07-03 0000718937 us-gaap:CostOfSalesMember 2019-03-30 2019-06-28 0000718937 us-gaap:CostOfSalesMember 2020-01-04 2020-07-03 0000718937 us-gaap:CostOfSalesMember 2018-12-29 2019-06-28 0000718937 us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-04 2020-07-03 0000718937 us-gaap:GeneralAndAdministrativeExpenseMember 2019-03-30 2019-06-28 0000718937 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-04 2020-07-03 0000718937 us-gaap:GeneralAndAdministrativeExpenseMember 2018-12-29 2019-06-28 0000718937 us-gaap:SellingAndMarketingExpenseMember 2020-04-04 2020-07-03 0000718937 us-gaap:SellingAndMarketingExpenseMember 2019-03-30 2019-06-28 0000718937 us-gaap:SellingAndMarketingExpenseMember 2020-01-04 2020-07-03 0000718937 us-gaap:SellingAndMarketingExpenseMember 2018-12-29 2019-06-28 0000718937 us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-04 2020-07-03 0000718937 us-gaap:ResearchAndDevelopmentExpenseMember 2019-03-30 2019-06-28 0000718937 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-04 2020-07-03 0000718937 us-gaap:ResearchAndDevelopmentExpenseMember 2018-12-29 2019-06-28 0000718937 staa:OmnibusPlanMember 2020-01-04 2020-07-03 0000718937 staa:OmnibusPlanMember us-gaap:EmployeeStockOptionMember 2020-01-04 2020-07-03 0000718937 staa:OmnibusPlanMember us-gaap:RestrictedStockMember srt:MinimumMember 2020-01-04 2020-07-03 0000718937 staa:OmnibusPlanMember us-gaap:RestrictedStockMember srt:MaximumMember 2020-01-04 2020-07-03 0000718937 staa:OmnibusPlanMember us-gaap:RestrictedStockMember 2020-07-03 0000718937 us-gaap:RestrictedStockMember 2020-01-03 0000718937 us-gaap:RestrictedStockUnitsRSUMember 2020-01-03 0000718937 us-gaap:RestrictedStockUnitsRSUMember 2020-07-03 0000718937 staa:UnvestedRestrictedStockMember 2019-03-30 2019-06-28 0000718937 staa:UnvestedRestrictedStockMember 2018-12-29 2019-06-28 0000718937 staa:RestrictedStockAwardsAndRestrictedStockUnitsMember 2019-03-30 2019-06-28 0000718937 staa:RestrictedStockAwardsAndRestrictedStockUnitsMember 2018-12-29 2019-06-28 0000718937 us-gaap:EmployeeStockOptionMember 2020-04-04 2020-07-03 0000718937 us-gaap:EmployeeStockOptionMember 2019-03-30 2019-06-28 0000718937 us-gaap:EmployeeStockOptionMember 2020-01-04 2020-07-03 0000718937 us-gaap:EmployeeStockOptionMember 2018-12-29 2019-06-28 0000718937 staa:RestrictedStockAwardsAndRestrictedStockUnitsMember 2020-04-04 2020-07-03 0000718937 staa:RestrictedStockAwardsAndRestrictedStockUnitsMember 2019-03-30 2019-06-28 0000718937 staa:RestrictedStockAwardsAndRestrictedStockUnitsMember 2020-01-04 2020-07-03 0000718937 staa:NonConsignmentSalesMember 2020-04-04 2020-07-03 0000718937 staa:NonConsignmentSalesMember 2019-03-30 2019-06-28 0000718937 staa:NonConsignmentSalesMember 2020-01-04 2020-07-03 0000718937 staa:NonConsignmentSalesMember 2018-12-29 2019-06-28 0000718937 staa:ConsignmentSalesMember 2020-04-04 2020-07-03 0000718937 staa:ConsignmentSalesMember 2019-03-30 2019-06-28 0000718937 staa:ConsignmentSalesMember 2020-01-04 2020-07-03 0000718937 staa:ConsignmentSalesMember 2018-12-29 2019-06-28 staa:Country 0000718937 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember staa:OtherCountriesMember srt:MaximumMember 2020-01-04 2020-07-03 0000718937 us-gaap:GeographicDistributionDomesticMember 2020-04-04 2020-07-03 0000718937 us-gaap:GeographicDistributionDomesticMember 2019-03-30 2019-06-28 0000718937 us-gaap:GeographicDistributionDomesticMember 2020-01-04 2020-07-03 0000718937 us-gaap:GeographicDistributionDomesticMember 2018-12-29 2019-06-28 0000718937 country:CN us-gaap:GeographicDistributionForeignMember 2020-04-04 2020-07-03 0000718937 country:CN us-gaap:GeographicDistributionForeignMember 2019-03-30 2019-06-28 0000718937 country:CN us-gaap:GeographicDistributionForeignMember 2020-01-04 2020-07-03 0000718937 country:CN us-gaap:GeographicDistributionForeignMember 2018-12-29 2019-06-28 0000718937 country:JP us-gaap:GeographicDistributionForeignMember 2020-04-04 2020-07-03 0000718937 country:JP us-gaap:GeographicDistributionForeignMember 2019-03-30 2019-06-28 0000718937 country:JP us-gaap:GeographicDistributionForeignMember 2020-01-04 2020-07-03 0000718937 country:JP us-gaap:GeographicDistributionForeignMember 2018-12-29 2019-06-28 0000718937 staa:OtherCountriesMember us-gaap:GeographicDistributionForeignMember 2020-04-04 2020-07-03 0000718937 staa:OtherCountriesMember us-gaap:GeographicDistributionForeignMember 2019-03-30 2019-06-28 0000718937 staa:OtherCountriesMember us-gaap:GeographicDistributionForeignMember 2020-01-04 2020-07-03 0000718937 staa:OtherCountriesMember us-gaap:GeographicDistributionForeignMember 2018-12-29 2019-06-28 0000718937 us-gaap:GeographicDistributionForeignMember 2020-04-04 2020-07-03 0000718937 us-gaap:GeographicDistributionForeignMember 2019-03-30 2019-06-28 0000718937 us-gaap:GeographicDistributionForeignMember 2020-01-04 2020-07-03 0000718937 us-gaap:GeographicDistributionForeignMember 2018-12-29 2019-06-28 0000718937 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember staa:OphthalmicSurgicalProductMember 2020-01-04 2020-07-03 staa:Segment 0000718937 staa:ImplantableCollamerLensesMember 2020-04-04 2020-07-03 0000718937 staa:ImplantableCollamerLensesMember 2019-03-30 2019-06-28 0000718937 staa:ImplantableCollamerLensesMember 2020-01-04 2020-07-03 0000718937 staa:ImplantableCollamerLensesMember 2018-12-29 2019-06-28 0000718937 staa:IntraocularLensesMember 2020-04-04 2020-07-03 0000718937 staa:IntraocularLensesMember 2019-03-30 2019-06-28 0000718937 staa:IntraocularLensesMember 2020-01-04 2020-07-03 0000718937 staa:IntraocularLensesMember 2018-12-29 2019-06-28 0000718937 staa:OtherSurgicalProductsMember 2020-04-04 2020-07-03 0000718937 staa:OtherSurgicalProductsMember 2019-03-30 2019-06-28 0000718937 staa:OtherSurgicalProductsMember 2020-01-04 2020-07-03 0000718937 staa:OtherSurgicalProductsMember 2018-12-29 2019-06-28 0000718937 staa:CustomerOneMember us-gaap:SalesRevenueNetMember 2020-04-04 2020-07-03 0000718937 staa:CustomerOneMember us-gaap:SalesRevenueNetMember 2020-01-04 2020-07-03 0000718937 staa:CustomerOneMember us-gaap:SalesRevenueNetMember 2019-03-30 2019-06-28 0000718937 staa:CustomerOneMember us-gaap:SalesRevenueNetMember 2018-12-29 2019-06-28 0000718937 staa:CustomerOneMember us-gaap:AccountsReceivableMember 2020-01-04 2020-07-03 0000718937 staa:CustomerOneMember us-gaap:AccountsReceivableMember 2018-12-29 2020-01-03

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended:    July 3, 2020

Or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission file number: 0-11634

 

STAAR SURGICAL COMPANY

(Exact Name of Registrant as Specified in its Charter)

 

Delaware

95-3797439

(State or Other Jurisdiction of

Incorporation or Organization)

(I.R.S. Employer

Identification No.)

25651 Atlantic Ocean Drive
Lake Forest, California

 

92630

(Address of Principal Executive Offices)

(Zip Code)

 

(626) 303-7902

(Registrant’s Telephone Number, Including Area Code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common

STAA

NASDAQ

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes      No 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

Accelerated filer

Non-accelerated filer

 

Smaller reporting company

Emerging growth company

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes      No 

The registrant has 45,806,406 shares of common stock, par value $0.01 per share, issued and outstanding as of July 31, 2020.

 


STAAR SURGICAL COMPANY

 

INDEX

 

 

 

 

PAGE

NUMBER

 

 

 

 

PART I – FINANCIAL INFORMATION

 

1

 

 

 

 

ITEM 1

FINANCIAL STATEMENTS

 

1

 

 

 

 

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

19

 

 

 

 

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

24

 

 

 

 

ITEM 4.

CONTROLS AND PROCEDURES

 

25

 

 

 

 

PART II – OTHER INFORMATION

 

25

 

 

 

 

ITEM 1.

LEGAL PROCEEDINGS

 

25

 

 

 

 

ITEM 1A.

RISK FACTORS

 

25

 

 

 

 

ITEM 4.

MINE SAFETY DISCLOSURES

 

25

 

 

 

 

ITEM 5.

OTHER INFORMATION

 

26

 

 

 

 

ITEM 6.

EXHIBITS

 

26

 

 

 


PART I – FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

STAAR SURGICAL COMPANY

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except par value amounts)

(Unaudited)

 

 

 

July 3, 2020

 

 

January 3, 2020

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

116,315

 

 

$

119,968

 

Accounts receivable trade, net of allowance of doubtful accounts of

   $52 and $88, respectively

 

 

39,469

 

 

 

30,996

 

Inventories, net

 

 

17,836

 

 

 

17,142

 

Prepayments, deposits and other current assets

 

 

8,897

 

 

 

6,560

 

Total current assets

 

 

182,517

 

 

 

174,666

 

Property, plant and equipment, net

 

 

21,478

 

 

 

17,065

 

Finance lease right-of-use assets, net

 

 

687

 

 

 

1,867

 

Operating lease right-of-use assets, net

 

 

5,587

 

 

 

6,684

 

Intangible assets, net

 

 

280

 

 

 

296

 

Goodwill

 

 

1,785

 

 

 

1,786

 

Deferred income taxes

 

 

5,114

 

 

 

3,750

 

Other assets

 

 

591

 

 

 

751

 

Total assets

 

$

218,039

 

 

$

206,865

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Line of credit

 

$

1,325

 

 

$

1,827

 

Accounts payable

 

 

8,890

 

 

 

8,050

 

Obligations under finance leases

 

 

493

 

 

 

560

 

Obligations under operating leases

 

 

2,355

 

 

 

2,700

 

Allowance for sales returns

 

 

4,285

 

 

 

3,644

 

Other current liabilities

 

 

14,241

 

 

 

17,697

 

Total current liabilities

 

 

31,589

 

 

 

34,478

 

Obligations under finance leases

 

 

108

 

 

 

366

 

Obligations under operating leases

 

 

3,320

 

 

 

4,086

 

Asset retirement obligations

 

 

212

 

 

 

211

 

Pension liability

 

 

8,136

 

 

 

7,840

 

Total liabilities

 

 

43,365

 

 

 

46,981

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Common stock, $0.01 par value; 60,000 shares authorized: 45,788 and

   44,822 shares issued and outstanding at July 3, 2020 and

   January 3, 2020, respectively

 

 

458

 

 

 

448

 

Additional paid-in capital

 

 

320,235

 

 

 

304,288

 

Accumulated other comprehensive loss

 

 

(2,909

)

 

 

(3,048

)

Accumulated deficit

 

 

(143,110

)

 

 

(141,804

)

Total stockholders’ equity

 

 

174,674

 

 

 

159,884

 

Total liabilities and stockholders’ equity

 

$

218,039

 

 

$

206,865

 

 

See accompanying notes to the condensed consolidated financial statements.

 

1


STAAR SURGICAL COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited)

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Net sales

 

$

35,194

 

 

$

39,664

 

 

$

70,381

 

 

$

72,247

 

Cost of sales

 

 

10,764

 

 

 

9,765

 

 

 

21,191

 

 

 

18,168

 

Gross profit

 

 

24,430

 

 

 

29,899

 

 

 

49,190

 

 

 

54,079

 

Selling, general and administrative expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

 

7,848

 

 

 

7,508

 

 

 

15,817

 

 

 

14,345

 

Marketing and selling

 

 

10,326

 

 

 

11,682

 

 

 

21,354

 

 

 

21,825

 

Research and development

 

 

7,311

 

 

 

6,098

 

 

 

14,209

 

 

 

11,733

 

Total selling, general and administrative expenses

 

 

25,485

 

 

 

25,288

 

 

 

51,380

 

 

 

47,903

 

Operating income (loss)

 

 

(1,055

)

 

 

4,611

 

 

 

(2,190

)

 

 

6,176

 

Other income (expense), net:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income, net

 

 

20

 

 

 

259

 

 

 

236

 

 

 

530

 

Gain (loss) on foreign currency transactions

 

 

388

 

 

 

11

 

 

 

(80

)

 

 

(237

)

Royalty income

 

 

52

 

 

 

163

 

 

 

146

 

 

 

334

 

Other income (expense), net

 

 

(21

)

 

 

1

 

 

 

(20

)

 

 

98

 

Total other income, net

 

 

439

 

 

 

434

 

 

 

282

 

 

 

725

 

Income (loss) before income taxes

 

 

(616

)

 

 

5,045

 

 

 

(1,908

)

 

 

6,901

 

Provision (benefit) for income taxes

 

 

556

 

 

 

1,131

 

 

 

(602

)

 

 

1,620

 

Net income (loss)

 

$

(1,172

)

 

$

3,914

 

 

$

(1,306

)

 

$

5,281

 

Net income (loss) per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

(0.03

)

 

$

0.09

 

 

$

(0.03

)

 

$

0.12

 

Diluted

 

$

(0.03

)

 

$

0.08

 

 

$

(0.03

)

 

$

0.11

 

Weighted average shares outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

45,354

 

 

 

44,479

 

 

 

45,152

 

 

 

44,357

 

Diluted

 

 

45,354

 

 

 

46,733

 

 

 

45,152

 

 

 

46,842

 

 

See accompanying notes to the condensed consolidated financial statements.

2


STAAR SURGICAL COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(In thousands)

(Unaudited)

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Net income (loss)

 

$

(1,172

)

 

$

3,914

 

 

$

(1,306

)

 

$

5,281

 

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Defined benefit plans:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net change in plan assets

 

 

(28

)

 

 

(614

)

 

 

(53

)

 

 

(640

)

Reclassification into other income, net

 

 

72

 

 

 

28

 

 

 

142

 

 

 

54

 

Foreign currency translation loss

 

 

113

 

 

 

382

 

 

 

86

 

 

 

339

 

Tax effect

 

 

(40

)

 

 

(55

)

 

 

(36

)

 

 

(35

)

Other comprehensive income (loss), net of tax

 

 

117

 

 

 

(259

)

 

 

139

 

 

 

(282

)

Comprehensive income (loss)

 

$

(1,055

)

 

$

3,655

 

 

$

(1,167

)

 

$

4,999

 

 

See accompanying notes to the condensed consolidated financial statements.

 

3


STAAR SURGICAL COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands)

(Unaudited)

 

 

 

Three Months Ended

 

 

 

Common

Stock Shares

 

 

Common

Stock Par

Value

 

 

Additional

Paid-In

Capital

 

 

Accumulated

Other

Compre-

hensive

Income

(Loss)

 

 

Accumulated

Deficit

 

 

Total

 

Balance, at April 3, 2020

 

 

45,105

 

 

$

451

 

 

$

309,480

 

 

$

(3,026

)

 

$

(141,938

)

 

$

164,967

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,172

)

 

 

(1,172

)

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

117

 

 

 

 

 

 

117

 

Common stock issued upon exercise of options

 

 

681

 

 

 

7

 

 

 

7,546

 

 

 

 

 

 

 

 

 

7,553

 

Stock-based compensation

 

 

 

 

 

 

 

 

3,209

 

 

 

 

 

 

 

 

 

3,209

 

Vested restricted stock

 

 

2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, at July 3, 2020

 

 

45,788

 

 

$

458

 

 

$

320,235

 

 

$

(2,909

)

 

$

(143,110

)

 

$

174,674

 

Balance, at March 29, 2019

 

 

44,447

 

 

$

444

 

 

$

292,722

 

 

$

(1,343

)

 

$

(154,485

)

 

$

137,338

 

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3,914

 

 

 

3,914

 

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

(259

)

 

 

 

 

 

(259

)

Common stock issued upon exercise of options

 

 

52

 

 

 

1

 

 

 

486

 

 

 

 

 

 

 

 

 

487

 

Stock-based compensation

 

 

 

 

 

 

 

 

2,855

 

 

 

 

 

 

 

 

 

2,855

 

Unvested restricted stock

 

 

11

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vested restricted stock

 

 

24

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, at June 28, 2019

 

 

44,534

 

 

$

445

 

 

$

296,063

 

 

$

(1,602

)

 

$

(150,571

)

 

$

144,335

 

 

See accompanying notes to the condensed consolidated financial statements.


4


STAAR SURGICAL COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (CONTINUED)

(In thousands)

(Unaudited)

 

 

 

Six Months Ended

 

 

 

Common

Stock Shares

 

 

Common

Stock Par

Value

 

 

Additional

Paid-In

Capital

 

 

Accumulated

Other

Compre-

hensive

Income

(Loss)

 

 

Accumulated

Deficit

 

 

Total

 

Balance, at January 3, 2020

 

 

44,822

 

 

$

448

 

 

$

304,288

 

 

$

(3,048

)

 

$

(141,804

)

 

$

159,884

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,306

)

 

 

(1,306

)

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

139

 

 

 

 

 

 

139

 

Common stock issued upon exercise of options

 

 

877

 

 

 

9

 

 

 

9,548

 

 

 

 

 

 

 

 

 

9,557

 

Stock-based compensation

 

 

 

 

 

 

 

 

6,399

 

 

 

 

 

 

 

 

 

6,399

 

Vested restricted stock

 

 

89

 

 

 

1

 

 

 

 

 

 

 

 

 

 

 

 

1

 

Balance, at July 3, 2020

 

 

45,788

 

 

$

458

 

 

$

320,235

 

 

$

(2,909

)

 

$

(143,110

)

 

$

174,674

 

Balance, at December 28, 2018

 

 

44,195

 

 

$

442

 

 

$

289,584

 

 

$

(1,320

)

 

$

(156,280

)

 

$

132,426

 

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

5,281

 

 

 

5,281

 

Impact of the adoption of lease accounting standard

 

 

 

 

 

 

 

 

 

 

 

 

 

 

113

 

 

 

113

 

Impact of adoption of nonemployee share-based payment standard

 

 

 

 

 

 

 

 

(315

)

 

 

 

 

 

315

 

 

 

 

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

(282

)

 

 

 

 

 

(282

)

Common stock issued upon exercise of options

 

 

126

 

 

 

1

 

 

 

1,109

 

 

 

 

 

 

 

 

 

1,110

 

Stock-based compensation

 

 

 

 

 

 

 

 

5,685

 

 

 

 

 

 

 

 

 

5,685

 

Unvested restricted stock

 

 

11

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vested restricted stock

 

 

202

 

 

 

2

 

 

 

 

 

 

 

 

 

 

 

 

2

 

Balance, at June 28, 2019

 

 

44,534

 

 

$

445

 

 

$

296,063

 

 

$

(1,602

)

 

$

(150,571

)

 

$

144,335

 

 

See accompanying notes to the condensed consolidated financial statements.

 

5


STAAR SURGICAL COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net income (loss)

 

$

(1,306

)

 

$

5,281

 

Adjustments to reconcile net income (loss) to net cash provided by

   operating activities:

 

 

 

 

 

 

 

 

Depreciation of property, plant, and equipment

 

 

1,518

 

 

 

1,983

 

Amortization of intangibles

 

 

17

 

 

 

17

 

Deferred income taxes

 

 

(1,369

)

 

 

393

 

Change in net pension liability

 

 

376

 

 

 

203

 

Loss on disposal of property and equipment

 

 

3

 

 

 

 

Stock-based compensation expense

 

 

5,839

 

 

 

5,220

 

Provision for sales returns and bad debts

 

 

605

 

 

 

(32

)

Inventory provision

 

 

816

 

 

 

787

 

Changes in working capital:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

(8,409

)

 

 

(6,533

)

Inventories

 

 

(932

)

 

 

106

 

Prepayments, deposits, and other current assets

 

 

(2,172

)

 

 

(1,154

)

Accounts payable

 

 

297

 

 

 

563

 

Other current liabilities

 

 

(3,471

)

 

 

(2,626

)

Net cash provided by (used in) operating activities

 

 

(8,188

)

 

 

4,208

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Acquisition of property and equipment

 

 

(4,210

)

 

 

(4,601

)

Acquisition of patents and licenses

 

 

 

 

 

(30

)

Net cash used in investing activities

 

 

(4,210

)

 

 

(4,631

)

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Repayment of finance lease obligations

 

 

(346

)

 

 

(681

)

Repayment on line of credit

 

 

(508

)

 

 

(999

)

Proceeds from the exercise of stock options

 

 

9,557

 

 

 

1,110

 

Proceeds from vested restricted stock

 

 

1

 

 

 

2

 

Net cash provided by (used in) financing activities

 

 

8,704

 

 

 

(568

)

Effect of exchange rate changes on cash, cash equivalents and restricted cash

 

 

41

 

 

 

243

 

Decrease in cash, cash equivalents and restricted cash

 

 

(3,653

)

 

 

(748

)

Cash, cash equivalents and restricted cash, at beginning of the period

 

 

119,968

 

 

 

103,999

 

Cash, cash equivalents and restricted cash, at end of the period

 

$

116,315

 

 

$

103,251

 

 

See accompanying notes to the condensed consolidated financial statements.

 

6


STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

 

Note 1 — Basis of Presentation and Significant Accounting Policies

The Condensed Consolidated Financial Statements of the Company present the financial position, results of operations, and cash flows of STAAR Surgical Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission. In accordance with those rules and regulations certain information and footnote disclosures normally included in the Comprehensive Financial Statements have been condensed or omitted pursuant to such rules and regulations. The Consolidated Balance Sheet as of January 3, 2020 was derived from the audited financial statements at that date, but does not include all the information and footnotes required by GAAP. These financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended January 3, 2020.

The Condensed Consolidated Financial Statements for the three and six months ended July 3, 2020 and June 28, 2019, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s financial condition and results of operations. The results of operations for the three and six months ended July 3, 2020 and June 28, 2019, are not necessarily indicative of the results to be expected for any other interim period or for the entire year.  

Each of the Company’s fiscal reporting periods ends on the Friday nearest to the quarter ending date and generally consists of 13 weeks.  Unless the context indicates otherwise “we,” “us,” the “Company,” and “STAAR” refer to STAAR Surgical Company and its consolidated subsidiaries.

Vendor Concentration

There were two vendors which accounted for over 27% of the Company’s consolidated accounts payable as of July 3, 2020.  There was one vendor which accounted for over 11% of the Company’s consolidated accounts payable as of January 3, 2020.  There were no vendors who accounted for over 10% of the Company’s consolidated purchases for the three months ended July 3, 2020.  There were three vendors who accounted for over 43% of the Company’s consolidated purchases for the six months ended July 3, 2020.  

Use of Estimates

During the COVID-19 pandemic, the Company believes it has used reasonable estimates and assumptions in determining valuation allowances for uncollectible trade receivables, sales returns reserves, obsolete and excess inventory reserves, deferred income taxes, and tax reserves, including valuation allowances for deferred tax assets, pension liabilities, evaluation of asset impairment, in determining the useful life of depreciable and definite-lived intangible assets, and in the variables and assumptions used to calculate and record stock-based compensation.  During the quarter ended July 3, 2020, the Company has experienced some delays in customer payments but is unaware of any material impairment of customer receivables.  The Company’s sales representatives throughout the world remain engaged with customers conducting online training and other educational courses which have been very well attended.  This activity has given the Company insight as to the impact to customers of COVID-19 and potential impairment of receivables.

Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted

On January 4, 2020 (beginning of fiscal year 2020), the Company adopted Accounting Standards Update (“ASU”) 2016‑13, “Financial Instruments – Credit Losses (Topic 326):  Measurement of Credit Losses on Financial Instruments,” which (i) significantly changes the impairment model for most financial assets that are measured at amortized cost and certain other instruments from an incurred loss model to an expected loss model; and (ii) provides for recording credit losses on available-for-sale debt securities through an allowance account.  ASU 2016-13 also requires certain incremental disclosures.  Subsequently, the FASB issued ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2020-02 and ASU 2020-03 to clarify and improve ASU 2016-13.  The adoption of ASU 2016-13 did not have a material impact on the Condensed Consolidated Financial Statements.

On January 4, 2020 (beginning of fiscal year 2020), the Company adopted ASU 2018-13, “Fair Value Measurement (Topic 820):  Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement,” which modifies certain disclosures requirements for reporting fair value measurements.  The adoption of ASU 2018-13 did not have a material impact on the Condensed Consolidated Financial Statements.

7


STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

 

Note 1 — Basis of Presentation and Significant Accounting Policies (Continued)

Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted (Continued)

On January 4, 2020 (beginning of fiscal year 2020), the Company adopted ASU 2018-14, “Compensation – Retirement Benefits – Defined Benefit Plans – General (Subtopic 715-20); Disclosure Framework – Changes in the Disclosure Requirement for Defined Benefit Plans,” which modifies disclosure requirements for employers that sponsor defined benefit pension or other post retirement plans.  The adoption of ASU 2018-14 did not have a material impact on the Condensed Consolidated Financial Statements.

In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740):  Simplifying the Accounting for Income Taxes.” ASU 2019-12 removes the following exceptions:  exception to the incremental approach for intra period tax allocation; exception to accounting for basis differences when there are ownership changes in foreign investments; and exception to interim period tax accounting for year to date losses that exceed anticipated losses.  ASU 2019-12 also improves financial reporting for franchise taxes that are partially based on income; transactions with a government that result in a step up in the tax basis of goodwill; separate financial statements of legal entities that are not subject to tax; and enacted changes in tax laws in interim periods.  ASU 2019-12 is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years.  Early adoption is permitted.  The Company will adopt this standard as of January 2, 2021 (beginning of fiscal year 2021) and is currently evaluating the disclosure requirements and its effect on the Condensed Consolidated Financial Statements.

Note 2 — Inventories

Inventories, net are stated at the lower of cost and net realizable value, determined on a first-in, first-out basis and consisted of the following (in thousands):

 

 

 

July 3, 2020

 

 

January 3, 2020

 

Raw materials and purchased parts

 

$

1,606

 

 

$

3,334

 

Work in process

 

 

4,997

 

 

 

1,870

 

Finished goods

 

 

12,487

 

 

 

12,976

 

Total inventories, gross

 

 

19,090

 

 

 

18,180

 

Less inventory reserves

 

 

1,254

 

 

 

1,038

 

Total inventories, net

 

$

17,836

 

 

$

17,142

 

 

Note 3 — Prepayments, Deposits, and Other Current Assets

Prepayments, deposits, and other current assets consisted of the following (in thousands):

 

 

July 3, 2020

 

 

January 3, 2020

 

Prepayments and deposits

 

$

5,106

 

 

$

3,031

 

Prepaid insurance

 

 

726

 

 

 

1,488

 

Consumption tax receivable

 

 

661

 

 

 

875

 

Value added tax (VAT) receivable

 

 

1,313

 

 

 

713

 

BVG (Swiss Pension) prepayment

 

 

451

 

 

 

 

Other(1)

 

 

640

 

 

 

453

 

Total prepayments, deposits and other current assets

 

$

8,897

 

 

$

6,560

 

 

(1)

No individual item in “other current assets” exceeds 5% of the total prepayments, deposits and other current assets.

8


STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

 

Note 4 — Property, Plant and Equipment

Property, plant and equipment, net consisted of the following (in thousands):

 

 

July 3, 2020

 

 

January 3, 2020

 

Machinery and equipment

 

$

20,970

 

 

$

17,173

 

Computer equipment and software

 

 

6,593

 

 

 

6,244

 

Furniture and fixtures

 

 

4,561

 

 

 

4,169

 

Leasehold improvements

 

 

11,100

 

 

 

10,151

 

Construction in process

 

 

8,889

 

 

 

8,477

 

Total property, plant and equipment, gross

 

 

52,113

 

 

 

46,214

 

Less accumulated depreciation

 

 

30,635

 

 

 

29,149

 

Total property, plant and equipment, net

 

$

21,478

 

 

$

17,065

 

 

Note 5 –Intangible Assets

Intangible assets, net consisted of the following (in thousands):

 

 

 

July 3, 2020

 

 

January 3, 2020

 

Long-lived amortized intangible assets

 

Gross

Carrying

Amount

 

 

Accumulated

Amortization

 

 

Net

 

 

Gross

Carrying

Amount

 

 

Accumulated

Amortization

 

 

Net

 

Patents and licenses

 

$

9,356

 

 

$

(9,076

)

 

$

280

 

 

$

9,353

 

 

$

(9,057

)

 

$

296

 

 

Note 6 – Other Current Liabilities

Other current liabilities consisted of the following (in thousands):

 

 

 

July 3, 2020

 

 

January 3, 2020

 

Accrued salaries and wages

 

$

5,752

 

 

$

4,400

 

Accrued bonuses

 

 

 

 

 

4,184

 

Accrued insurance

 

 

372

 

 

 

1,346

 

Income taxes payable

 

 

2,579

 

 

 

2,710

 

Accrued consumption tax

 

 

750

 

 

 

1,164

 

Accrued professional fees for clinical trials

 

 

968

 

 

 

567

 

Marketing obligations

 

 

838

 

 

 

633

 

Other(1)

 

 

2,982

 

 

 

2,693

 

Total other current liabilities

 

$

14,241

 

 

$

17,697

 

 

(1)

No individual item in “Other” exceeds 5% of the other current liabilities.

Note 7 – Lines of Credit

Since 1998, the Company’s wholly owned Japanese subsidiary, STAAR Japan, has had an agreement with Mizuho Bank which provides for borrowings of up to 500,000,000 Yen, at an interest rate equal to the uncollateralized overnight call rate (approximately 0.06% as of July 3, 2020) plus a 0.50% spread, and may be renewed quarterly (the current line expires on August 21, 2020).  The credit facility is not collateralized.  The Company had 142,500,000 Yen and 197,500,000 Yen outstanding on the line of credit as of July 3, 2020 and January 3, 2020, respectively (approximately $1,325,000 and $1,827,000 based on the foreign exchange rates on July 3, 2020 and January 3, 2020, respectively), which approximates fair value due to the short-term maturity and market interest rates of the line of credit.  In case of default, the interest rate will be increased to 14% per annum.  There was 357,500,000 Yen and 302,500,000 Yen available for borrowing as of July 3, 2020 and  January 3, 2020, respectively (approximately $3,325,000 and $2,798,000 based on the foreign exchange rate on July 3, 2020 and January 3, 2020, respectively).  At maturity on August 21, 2020, the Company expects to renew this line of credit for an additional three months, with similar terms.

9


STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

 

Note 7 – Lines of Credit (Continued)

In September 2013, the Company’s wholly owned Swiss subsidiary, STAAR Surgical AG, entered into a framework agreement for loans (“framework agreement”) with Credit Suisse (the “Bank”). The framework agreement provides for borrowings of up to 1,000,000 CHF (Swiss Francs) (approximately $1,100,000 and $1,000,000 at the rate of exchange on July 3, 2020 and January 3, 2020 respectively), to be used for working capital purposes. Accrued interest and 0.25% commissions on average outstanding borrowings is payable quarterly and the interest rate will be determined by the Bank based on the then prevailing market conditions at the time of borrowing. The framework agreement is automatically renewed on an annual basis based on the same terms assuming there is no default. The framework agreement may be terminated by either party at any time in accordance with its general terms and conditions. The framework agreement is not collateralized and contains certain conditions such as providing the Bank with audited financial statements annually and notice of significant events or conditions, as defined in the framework agreement. The Bank may also declare all amounts outstanding to be immediately due and payable upon a change of control or a “material qualification” in STAAR Surgical independent auditors’ report, as defined. There were no borrowings outstanding as of July 3, 2020 and January 3, 2020.

The Company is in compliance with covenants of its credit facilities and lines of credit as of July 3, 2020.

Note 8 – Leases

Finance Leases

The Company entered into finance leases primarily related to purchases of equipment used for manufacturing or computer-related equipment.  These finance leases are two to five years in length and have fixed payment amounts for the term of the contract and have options to purchase the assets at the end of the lease term.  Supplemental balance sheet information related to finance leases consisted of the following (dollars in thousands):

 

 

 

July 3, 2020

 

 

January 3, 2020

 

Machinery and equipment

 

$

568

 

 

$

1,885

 

Computer equipment and software

 

 

860

 

 

 

912

 

Furniture and fixtures

 

 

 

 

 

102

 

Leasehold improvements

 

 

 

 

 

27

 

Finance lease right-of-use assets, gross

 

 

1,428

 

 

 

2,926

 

Less accumulated depreciation

 

 

741

 

 

 

1,059

 

Finance lease right-of-use assets, net

 

$

687

 

 

$

1,867

 

 

 

 

 

 

 

 

 

 

Total finance lease liability

 

$

601

 

 

$

926

 

Weighted-average remaining lease term (in years)

 

 

2.0

 

 

 

1.1

 

Weighted-average discount rate

 

 

5.40

%

 

 

6.17

%

 

Supplemental cash flow information related to finance leases consisted of the following (dollars in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Amortization of finance lease right-of-use asset

 

$

50

 

 

$

145

 

 

$

167

 

 

$

306

 

Interest on finance lease liabilities

 

 

8

 

 

 

22

 

 

 

18

 

 

 

41

 

Cash paid for amounts included in the measurement of finance lease liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating cash flows

 

 

8

 

 

 

22

 

 

 

18

 

 

 

41

 

Financing cash flows

 

 

110

 

 

 

316

 

 

 

346

 

 

 

681

 

Right-of-use assets obtained in exchange for new finance lease liabilities

 

 

22

 

 

 

37

 

 

 

22

 

 

 

679

 

10


STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

 

Note 8 – Leases (Continued)

Operating Leases

The Company entered into operating leases primarily related to real property (office, manufacturing and warehouse facilities), automobiles and copiers.  These operating leases are two to five years in length with options to extend.  The Company did not include any lease extensions in the initial valuation unless the Company was reasonably certain to extend the lease.  Depending on the lease, there are those with fixed payment amounts for the entire length of the contract or payments which increase periodically as noted in the contract or increased at an inflation rate indicator.  For operating leases that increase using an inflation rate indicator, the Company used the inflation rate at the time the lease was entered into for the length of the lease term.  Supplemental balance sheet information related to operating leases consisted of the following (dollars in thousands):

 

 

 

July 3, 2020

 

 

January 3, 2020

 

Machinery and equipment

 

$

837

 

 

$

765

 

Computer equipment and software

 

 

462

 

 

 

462

 

Real property

 

 

11,247

 

 

 

11,116

 

Operating lease right-of-use assets, gross

 

 

12,546

 

 

 

12,343

 

Less accumulated depreciation

 

 

6,959

 

 

 

5,659

 

Operating lease right-of-use assets, net

 

$

5,587

 

 

$

6,684

 

 

 

 

 

 

 

 

 

 

Total operating lease liability

 

$

5,675

 

 

$

6,786

 

Weighted-average remaining lease term (in years)

 

 

2.2

 

 

 

2.3

 

Weighted-average discount rate

 

 

1.75

%

 

 

1.82

%

 

Supplemental cash flow information related to operating leases was as follows (dollars in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Operating lease cost

 

$

746

 

 

$

683

 

 

$

1,486

 

 

$

1,294

 

Cash paid for amounts included in the measurement of operating lease liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating cash flows

 

 

763

 

 

 

691

 

 

 

1,501

 

 

 

1,292

 

Right-of-use assets obtained in exchange for new operating lease liabilities

 

 

249

 

 

 

1,193

 

 

 

318

 

 

 

2,657

 

Future Minimum Lease Commitments

Estimated future minimum lease payments under operating and finance leases having initial or remaining non-cancelable lease terms more than one year as of July 3, 2020 is as follows (in thousands):

 

As of July 3, 2020

12 Months Ended

 

Operating Leases

 

 

Finance Leases

 

June 2021

 

$

2,473

 

 

$

510

 

June 2022

 

 

1,394

 

 

 

84

 

June 2023

 

 

1,216

 

 

 

14

 

June 2024

 

 

665

 

 

 

11

 

June 2025

 

 

171

 

 

 

 

Thereafter

 

 

 

 

 

 

Total minimum lease payments, including interest

 

$

5,919

 

 

$

619

 

Less amounts representing interest

 

 

244

 

 

 

18

 

Total minimum lease payments

 

$

5,675

 

 

$

601

 

 

11


STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

 

Note 9 Income Taxes

The Company recorded an income tax provision (benefit) as follows (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Provision (benefit) for income taxes

 

$

556

 

 

$

1,131

 

 

$

(602

)

 

$

1,620

 

The Company recorded income taxes of $556,000 and $1,131,000 for the three months ended July 3, 2020 and June 28, 2019, respectively, primarily due to pre-tax income generated in certain foreign jurisdictions.  Also included in the three months ended June 28, 2019 were withholding taxes on foreign operations.  The Company recorded an income tax benefit of $602,000 for the six months ended July 3, 2020 due to the income tax benefit from the release of its U.S. valuation allowance, offset by income tax expense from profits generated from its foreign operations.  The Company recorded income taxes of $1,620,000 for the six months ended June 28, 2019, primarily due to pre-tax income generated in certain foreign jurisdictions and withholding taxes on foreign operations.  The Company’s quarterly provision for income taxes is determined by estimating an annual effective tax rate.  This estimate may fluctuate throughout the year as new information becomes available affecting its underlying assumptions.  In the fourth quarter of fiscal year 2019, the Company reversed all previously recorded withholding taxes recorded for 2019, at which time the Company formed STAAR Surgical UK Limited as a holding company for its foreign operations.  Based on the current tax treaties between the U.S., United Kingdom and Switzerland, the Company will no longer accrue for Switzerland withholding taxes on foreign earnings after fiscal 2018 (see also Note 10 in its fiscal 2019 Form 10-K for more information). There are no unrecognized tax benefits related to uncertain tax positions taken by the Company.   All earnings from the Company’s subsidiaries are not considered to be permanently reinvested.

The 2017 Tax Act subjects a U.S. shareholder to tax on Global Intangible Low Tax Income (“GILTI”) earned by certain foreign subsidiaries.  In general, GILTI is the excess of a U.S. shareholder’s total net foreign income over a deemed return on tangible assets.  The provision further allows a deduction of 50 percent of GILTI, however this deduction is limited by the Company’s U.S. taxable income.  The Company has elected to account for GILTI as a current period expense when incurred.

For the three and six months ended July 3, 2020, the Company included GILTI of $4,137,000 and $5,400,000, respectively, and for the three and six months ended June 28, 2019, included GILTI of $5,635,000 and $7,699,000, respectively, in U.S. gross income, which was fully offset by net operating loss carryforwards.  The Company was not able to utilize the deduction of 50 percent of GILTI, as this deduction is limited by the Company’s pre-GILTI U.S. taxable income.

The ultimate realization of deferred tax assets is dependent upon future generation of income during the periods in which temporary differences representing net future deductible amounts become deductible. Management considers the projected future income and tax planning strategies in making this assessment. As of fiscal year end 2019, the Company had three years of accumulated profits for federal income tax purposes as a result of GILTI.  However, the three-year income position is not solely determinative and, accordingly, management considers all other available positive and negative evidence in its analysis. This includes existing profits in foreign jurisdiction as well as projected future profits. As further described in Notes 1 and 10 of the Company’s fiscal 2019 Form 10-K, under the “incremental cash tax savings approach,” the Company recorded a valuation allowance release of $3,003,000 and $373,000 against the federal and certain states deferred tax assets, respectively.  During the six months ended July 3, 2020, the Company revised its global forecasts as a result of COVID-19, and released an additional $1,369,000 of valuation allowance.  As of July 3, 2020, the Company released approximately $4,745,000 of valuation allowance on its deferred tax assets in the U.S. jurisdiction utilizing the incremental cash tax savings approach.

Under the incremental cash tax savings approach, the U.S. valuation allowances of $36,530,000, will remain as the usage of the remaining net operating losses and deferred tax assets will not result in cash tax savings and therefore provide no additional benefit.  As of July 3, 2020, the Company had net deferred tax assets in the U.S. of $4,881,000, which consisted of the federal and state valuation allowance release of $4,439,000 and $306,000, respectively, and the refundable alternative minimum tax credit of $136,000.  

On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (“CARES”) Act was enacted and signed into law.  The Company reviewed the provisions of the CARES Act, but does not expect it to have a material impact to its tax provision (also see note 15). 

12


STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

 

Note 9 Income Taxes (Continued)

On July 20, the U.S. Treasury issued final regulations for addressing the treatment of foreign income that is subject to a high rate of foreign tax (the GILTI high-tax exclusion). The final regulations allow companies to exclude certain high-taxed income from their GILTI calculation.  The GILTI high-tax exclusion applies if the effective foreign tax rate is 90% or more of the rate that would apply if the income were subject to the maximum US rate of tax specified in section 11 (currently 18.9%, based on a maximum rate of 21%).  The final regulations also provide that the GILTI high-tax exclusion is an annual election made each year and is retroactive to years beginning after December 31, 2017.  As the regulations were finalized on July 20, 2020, after the current reporting period, the impact if any on the financial statements will be reported in the third quarter.  Management is currently evaluating the effect if any this election would have on their financial statements.

Note 10 – Defined Benefit Pension Plans

 

The Company has defined benefit plans covering employees of its Switzerland and Japan operations.  The following table summarizes the components of net periodic pension cost recorded for the Company’s defined benefit pension plans (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Service cost(1)

 

$

320

 

 

$

248

 

 

$

639

 

 

$

480

 

Interest cost(2)

 

 

11

 

 

 

20

 

 

 

22

 

 

 

40

 

Expected return on plan assets(2)

 

 

(46

)

 

 

(34

)

 

 

(89

)

 

 

(67

)

Prior service credit(2),(3)

 

 

(8

)

 

 

(5

)

 

 

(17

)

 

 

(11

)

Actuarial loss recognized in current period(2),(3)

 

 

80

 

 

 

33

 

 

 

159

 

 

 

65

 

Net periodic pension cost

 

$

357

 

 

$

262

 

 

$

714

 

 

$

507

 

 

(1)

Recognized in selling general and administrative expenses on the Condensed Consolidated Statements of Income.

(2)

Recognized in other income (expense), net on the Condensed Consolidated Statements of Income.

(3)

Amounts reclassified from accumulated other comprehensive income (loss).

 

The Company currently is not required to and does not make contributions to its Japan pension plan.  The Company’s contributions to its Swiss pension plan are as follows (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Employer contribution

 

$

155

 

 

$

137

 

 

$

330

 

 

$

263

 

 

13


STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

 

Note 11 — Stockholders’ Equity

Stock-Based Compensation

The cost that has been charged against income for stock-based compensation is set forth below (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Employee stock options

 

$

2,505

 

 

$

2,162

 

 

$

4,737

 

 

$

3,592

 

Restricted stock

 

 

76

 

 

 

77

 

 

 

154

 

 

 

159

 

Restricted stock units

 

 

274

 

 

 

311

 

 

 

823

 

 

 

1,415

 

Nonemployee stock options

 

 

63

 

 

 

29

 

 

 

125

 

 

 

54

 

Total stock-based compensation expense

 

$

2,918

 

 

$

2,579

 

 

$

5,839

 

 

$

5,220

 

 

The Company recorded stock-based compensation costs in the following categories (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Cost of sales

 

$

30

 

 

$

22

 

 

$

52

 

 

$

36

 

General and administrative

 

 

1,209

 

 

 

1,018

 

 

 

2,294

 

 

 

1,796

 

Marketing and selling

 

 

812

 

 

 

690

 

 

 

1,867

 

 

 

1,861

 

Research and development

 

 

867

 

 

 

849

 

 

 

1,626

 

 

 

1,527

 

Total stock-based compensation expense, net

 

 

2,918

 

 

 

2,579

 

 

 

5,839

 

 

 

5,220

 

Amounts capitalized as part of inventory

 

 

291

 

 

 

276

 

 

 

560

 

 

 

465

 

Total stock-based compensation expense, gross

 

$

3,209

 

 

$

2,855

 

 

$

6,399

 

 

$

5,685

 

 

Incentive Plan

The Amended and Restated Omnibus Equity Incentive Plan (“the Plan”) provides for various forms of stock-based incentives. To date, of the available forms of awards under the Plan, the Company has granted only stock options, restricted stock, unrestricted share grants, and restricted stock units (“RSUs”). Options under the Plan are granted at fair market value on the date of grant, become exercisable generally over a three-year period, or as determined by the Board of Directors, and expire over periods not exceeding 10 years from the date of grant. Certain option and share awards provide for accelerated vesting if there is a change in control and pre-established financial metrics are met (as defined in the Plan). Grants of restricted stock outstanding under the Plan generally vest over periods of one to three years. Grants of RSUs outstanding under the Plan generally vest based on service, performance, or a combination of both.  As of July 3, 2020, there were 842,975 shares available for grant under the Plan

Assumptions

The fair value of each option award is estimated on the date of grant using a Black-Scholes option valuation model applying the weighted-average assumptions noted in the following table.  Expected volatilities are based on historical volatility of the Company’s stock. The expected term of options granted is derived from the historical exercises and post-vesting cancellations and represents the period of time that options granted are expected to be outstanding.  The Company has calculated an 6% estimated forfeiture rate based on historical forfeiture experience.  The risk-free rate is based on the U.S. Treasury yield curve corresponding to the expected term at the time of the grant.  

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Expected dividend yield

 

 

0

%

 

 

0

%

 

 

0

%

 

 

0

%

Expected volatility

 

 

53

%

 

 

53

%

 

 

53

%

 

 

53

%

Risk-free interest rate

 

 

0.31

%

 

 

2.05

%

 

 

0.53

%

 

 

2.41

%

Expected term (in years)

 

 

5.72

 

 

 

5.67

 

 

 

5.72

 

 

 

5.67

 

 

14


STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

 

Note 11 — Stockholders’ Equity (Continued)

Stock Options

A summary of stock option activity under the Plan for the six months ended July 3, 2020 is presented below:

 

 

 

Stock

Options

(in 000’s)

 

 

Minimum

Exercise

Price

 

 

Maximum

Exercise

Price

 

Outstanding at January 3, 2020

 

 

4,326

 

 

 

 

 

 

 

 

 

Granted

 

 

609

 

 

 

 

 

 

 

 

 

Exercised

 

 

(876

)

 

 

 

 

 

 

 

 

Forfeited or expired

 

 

(12

)

 

 

 

 

 

 

 

 

Outstanding at July 3, 2020

 

 

4,047

 

 

$

5.05

 

 

$

43.84

 

Exercisable at July 3, 2020

 

 

2,717

 

 

 

 

 

 

 

 

 

 

Restricted Stock and Restricted Stock Units

A summary of restricted stock and RSU activity under the Plan for the six months ended July 3, 2020 is presented below:

 

 

 

Restricted

Stock

(in 000’s)

 

 

Restricted

Stock

Units

(in 000’s)

 

Unvested at January 3, 2020

 

 

11

 

 

 

104

 

Granted

 

 

 

 

 

97

 

Vested

 

 

(11

)

 

 

(89

)

Forfeited or expired

 

 

 

 

 

(1

)

Unvested at July 3, 2020

 

 

 

 

 

111

 

 

Note 12 - Commitments and Contingencies

Litigation and Claims

From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of business.  These legal proceedings and other matters may relate to, among other things, contractual rights and obligations, employment matters, or claims of product liability.  STAAR maintains insurance coverage for various matters, including product liability and certain securities claims.  While the Company does not believe that any of the claims known is likely to have a material adverse effect on the Company’s financial condition or results of operations, new claims or unexpected results of existing claims could lead to significant financial harm.

Employment Agreements

The Company’s Chief Executive Officer entered into an employment agreement with the Company, effective March 1, 2015. She and certain officers have as provisions of their agreements certain rights, including continuance of cash compensation and benefits, upon a “change in control,” which may include an acquisition of substantially all its assets, or termination “without cause or for good reason” as defined in the employment agreements.

15


STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

 

Note 13 — Basic and Diluted Net Income (Loss) Per Share

The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands except per share amounts):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

$

(1,172

)

 

$

3,914

 

 

$

(1,306

)

 

$

5,281

 

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common shares outstanding

 

 

45,354

 

 

 

44,489

 

 

 

45,152

 

 

 

44,368

 

Less:  Unvested restricted stock

 

 

 

 

 

(10

)

 

 

 

 

 

(11

)

Denominator for basic calculation

 

 

45,354

 

 

 

44,479

 

 

 

45,152

 

 

 

44,357

 

Weighted average effects of potentially diluted common stock:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock options

 

 

 

 

 

2,149

 

 

 

 

 

 

2,292

 

Unvested restricted stock

 

 

 

 

 

97

 

 

 

 

 

 

185

 

Restricted stock units

 

 

 

 

 

8

 

 

 

 

 

 

8

 

Denominator for diluted calculation

 

 

45,354

 

 

 

46,733

 

 

 

45,152

 

 

 

46,842

 

Net income (loss) per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

(0.03

)

 

$

0.09

 

 

$

(0.03

)

 

$

0.12

 

Diluted

 

$

(0.03

)

 

$

0.08

 

 

$

(0.03

)

 

$

0.11

 

Because the Company had a net loss for the three and six months ended July 3, 2020, the number of diluted shares is equal to the number of basic shares.  The following table sets forth (in thousands) the weighted average number of options to purchase shares of common stock, restricted stock, and restricted stock units with either exercise prices or unrecognized compensation cost per share greater than the average market price per share of the Company’s common stock, which were not included in the calculation of diluted per share amounts because the effects would be anti-dilutive.

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Stock options

 

 

3,082

 

 

 

1,991

 

 

 

3,502

 

 

 

1,256

 

Restricted stock and restricted stock units

 

 

59

 

 

 

1

 

 

 

72

 

 

 

 

Total

 

 

3,141

 

 

 

1,992

 

 

 

3,574

 

 

 

1,256

 

 

16


STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

 

Note 14 — Disaggregation of Sales, Geographic Sales and Product Sales

In the following tables, sales are disaggregated by category, sales by geographic market and sales by product data.  The following breaks down sales into the following categories (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Non-consignment sales

 

$

23,446

 

 

$

35,556

 

 

$

53,846

 

 

$

63,822

 

Consignment sales

 

 

11,748

 

 

 

4,108

 

 

 

16,535

 

 

 

8,425

 

Total net sales

 

$

35,194

 

 

$

39,664

 

 

$

70,381

 

 

$

72,247

 

 

The Company markets and sells its products in over 75 countries and conducts its manufacturing in the United States.  Other than China and Japan, the Company does not conduct business in any country in which its sales exceed 10% of worldwide consolidated net sales. Sales are attributed to countries based on location of customers. The composition of the Company’s net sales to unaffiliated customers was as follows (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Domestic

 

$

882

 

 

$

2,114

 

 

$

2,621

 

 

$

4,066

 

Foreign:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

China

 

 

18,603

 

 

 

19,394

 

 

 

30,318

 

 

 

31,165

 

Japan

 

 

7,463

 

 

 

6,275

 

 

 

15,765

 

 

 

11,794

 

Other(1)

 

 

8,246

 

 

 

11,881

 

 

 

21,677

 

 

 

25,222

 

Total foreign sales

 

 

34,312

 

 

 

37,550

 

 

 

67,760

 

 

 

68,181

 

Total net sales

 

$

35,194

 

 

$

39,664

 

 

$

70,381

 

 

$

72,247

 

 

(1)

No other location individually exceeds 10% of the total sales.

100% of the Company’s sales are generated from the ophthalmic surgical product segment and the chief operating decision maker makes operating decisions and allocates resources based upon the consolidated operating results, and therefore the Company operates as one operating segment for financial reporting purposes. The Company’s principal products are implantable Collamer lenses (“ICLs”) used in refractive surgery and intraocular lenses (“IOLs”) used in cataract surgery.  The composition of the Company’s net sales by product line was as follows (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

ICLs

 

$

30,728

 

 

$

34,432

 

 

$

60,068

 

 

$

62,218

 

Other product sales

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

IOLs

 

 

2,561

 

 

 

3,874

 

 

 

6,555

 

 

 

7,891

 

Other surgical products

 

 

1,905

 

 

 

1,358

 

 

 

3,758

 

 

 

2,138

 

Total other product sales

 

 

4,466

 

 

 

5,232

 

 

 

10,313

 

 

 

10,029

 

Total net sales

 

$

35,194

 

 

$

39,664

 

 

$

70,381

 

 

$

72,247

 

 

One customer, the Company’s distributor in China, accounted for 53% and 43% of net sales for the three and six months ended July 3, 2020, respectively, and the same customer, accounted for 49% and 43% of net sales for the three and six months ended June 28, 2019, respectively.  As of July 3, 2020 and January 3, 2020, respectively, one customer, the Company’s distributor in China, accounted for 57% and 43% of consolidated trade receivables.

17


STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

 

Note 15 — COVID-19 and CARES Act Developments

 

In December 2019, COVID-19 surfaced and in March 2020, the World Health Organization declared a pandemic related to the rapid spread of COVID-19 around the world.  The impact of the COVID-19 outbreak on the businesses and the economy in the U.S. and the rest of the world is, and is expected to continue to be, uncertain and may be significant. Accordingly, the Company cannot predict the extent to which its financial condition and results of operation will be affected. On March 17, 2020, the Company suspended most of its production and non-essential business locations where employees can work from home.  A very limited number of manufacturing personnel remained at work for critical late staged processes, until the end of March 2020.  Manufacturing resumed on April 27, 2020.  The Company’s revenues have been adversely impacted, as customers in China were not able to carry out procedures during the month of February and the Company experienced a substantial slowdown in sales beginning March 20, 2020 in global geographies characterized as “hot spots” for the COVID 19 virus, including parts of Europe and North America.  In certain of these markets, sales have paused as elective surgeries are discouraged to support COVID-19 related needs.  The Company expects decreases in sales in certain geographies to continue through the remainder of 2020 as different geographies resume business activities on differing timelines.  

 

The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property.  The Company did not apply for or require financing available under the CARES Act and does not expect to do so given the strength of our balance sheet.  The Company will continue to monitor the impact that the CARES Act may have on its business, financial condition, results of operations, or liquidity.

 

18


 

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The matters addressed in this Item 2 that are not historical information constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Readers can recognize forward-looking statements by the use of words like “anticipate,” “estimate,” “expect,” “intend,” “plan,” “believe,” “will,” “should,” “forecast” and similar expressions in connection with any discussion of future operating or financial performance. In particular, these include statements about any of the following: any projections of or guidance as to earnings, revenue, sales, profit margins, expense rate, cash, effective tax rate, capital expense or any other financial items; the expected impact of the COVID-19 pandemic and related public health measures (including but not limited to their impact on sales, operations or clinical trials globally), the plans, strategies, and objectives of management for future operations or prospects for achieving such plans; statements regarding new, existing, or improved products, including but not limited to, expectations for success of new, existing, and improved products in the U.S. or international markets or government approval of a new or improved products (including the EVO family of lenses in the U.S. and the EDOF ICL for presbyopia internationally); commercialization of new or improved products; future economic conditions or size of market opportunities; expected costs of operations; statements of belief, including as to achieving 2020 business plans; expected regulatory activities and approvals, product launches, and any statements of assumptions underlying any of the foregoing.

Although we believe that the expectations reflected in these forward-looking statements are reasonable, such statements are inherently subject to risks and we can give no assurance that our expectations will prove to be correct. Actual results could differ from those described in this report because of numerous factors, many of which are beyond our control. These factors include, without limitation, risks and uncertainties related to the COVID-19 pandemic and related public health measures, and those described in in our Annual Report on Form 10-K in “Item 1A. Risk Factors” filed on February 26, 2020, as well as the updated risk factor disclosed herein.  We undertake no obligation to update these forward-looking statements after the date of this report to reflect future events or circumstances or to reflect actual outcomes.

The following discussion should be read in conjunction with the audited consolidated financial statements of STAAR, including the related notes, provided in this report.

Overview

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and companion delivery systems used to deliver the lenses into the eye. We are the world’s leading manufacturer of intraocular lenses for patients seeking refractive vision correction, and we also make lenses for use in surgery to treat cataracts. All the lenses we make are foldable, which allows the surgeon to insert them into the eye through a small incision during minimally invasive surgery. Refractive surgery is performed to treat the type of visual disorders that have traditionally been corrected using eyeglasses or contact lenses. We refer to our lenses used in refractive surgery as “implantable Collamer® lenses” or “ICLs.” The field of refractive surgery includes both lens-based procedures, using products like our ICL family of products, and laser-based procedures like LASIK. Successful refractive surgery can correct common vision disorders such as myopia, hyperopia, and astigmatism. Cataract surgery is a common outpatient procedure where the eye’s natural lens that has become cloudy with age is removed and replaced with an artificial lens called an intraocular lens (IOL) to restore the patient’s vision. STAAR employs a commercialization strategy that strives for sustainable profitable growth. Our goal is to position our refractive lenses throughout the world as primary and premium solutions for patients seeking visual freedom from wearing eyeglasses or contact lenses while achieving excellent visual acuity through refractive vision correction. We position our IOL lenses used in surgery that treats cataracts based on quality and value.

 

Recent Developments

While refractive procedures were down significantly or came to a halt in April and May in much of North America, Europe, Latin America, India and the Middle East, continuing recovery and growth were recorded in Japan, Korea and China.  The positive trending continued in July with China experiencing stronger than anticipated demand as the peak season began in earnest.  While COVID-19 hotspots and government public health mandates may reoccur moving forward, we anticipate less business interruption and continued increased interest in our EVO ICL lens-based refractive solutions in the third and fourth quarter of 2020. We also continue to believe that we will achieve a 20% share of the refractive procedure market in China by the end of the year. Assuming significant COVID-19 hotspots and government public health mandates do not reoccur and global economic improvement progresses, our outlook for the third quarter of 2020 currently anticipates a sequential revenue increase of over 20% from our second quarter of 2020 results which would then result in year-over-year double digit growth.  Also, we currently expect fourth quarter of 2020 revenue will be similar to third quarter of 2020.

19


 

We resumed production at our California manufacturing facilities on April 27, 2020 and anticipate that we will be able to meet the demand for both our Spheric and Toric EVO lenses through the remainder of 2020.  We are moving forward with our plans to restart manufacturing in our Nidau, Switzerland facility in 2021. With respect to our U.S. clinical trial for our EVO family of myopia lenses, assuming no material change in the current operating environment we anticipate that we will complete enrollment in the trial by the end of September.  Considering the subsequent six-month patient follow-up and time to prepare our data submission to the FDA, we believe we are on track for potential marketing approval and commercialization of EVO in the U.S. in the second half of 2021.

As previously disclosed, we received on July 2, 2020, CE Mark approval for our extended depth of focus or EDOF presbyopia lens, EVO Viva, that is designed to correct near, intermediate and distance vision. We will commence a phased-rollout beginning in Spain, Belgium and Germany. We anticipate the first implants will occur in September following physician training and certification.

Critical Accounting Policies

This Management’s Discussion and Analysis of Financial Condition and Results of Operations discusses and analyzes data in our unaudited Condensed Consolidated Financial Statements provided in this report, which we have prepared in accordance with U.S. generally accepted accounting principles. Preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Management bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual conditions may differ from our assumptions and actual results may differ from our estimates.

An accounting policy is deemed critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, if different estimates reasonably could have been used, or if changes in the estimate that are reasonably likely to occur could materially impact the financial statements. Management believes that there have been no significant changes during the six months ended July 3, 2020 to the items that we disclosed as our critical accounting policies and estimates in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended January 3, 2020.

Results of Operations

The following table shows the percentage of our total sales represented by certain items reflected in our Condensed Consolidated Statements of Operations for the periods indicated.

 

 

 

Percentage of Net Sales

for Three Months

 

 

Percentage of Net Sales

for Six Months

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

Net sales

 

 

100.0

%

 

 

100.0

%

 

 

100.0

%

 

 

100.0

%

Cost of sales

 

 

30.6

%

 

 

24.6

%

 

 

30.1

%

 

 

25.1

%

Gross profit

 

 

69.4

%

 

 

75.4

%

 

 

69.9

%

 

 

74.9

%

General and administrative

 

 

22.3

%

 

 

18.9

%

 

 

22.5

%

 

 

19.9

%

Marketing and selling

 

 

29.3

%

 

 

29.5

%

 

 

30.3

%

 

 

30.2

%

Research and development

 

 

20.8

%

 

 

15.4

%

 

 

20.2

%

 

 

16.3

%

Total selling, general and administrative

 

 

72.4

%

 

 

63.8

%

 

 

73.0

%

 

 

66.4

%

Operating income (loss)

 

 

(3.0

)%

 

 

11.6

%

 

 

(3.1

)%

 

 

8.5

%

Total other income (expense), net

 

 

1.2

%

 

 

1.1

%

 

 

0.4

%

 

 

1.0

%

Income (loss) before income taxes

 

 

(1.8

)%

 

 

12.7

%

 

 

(2.7

)%

 

 

9.5

%

Provision (benefit) for income taxes

 

 

1.5

%

 

 

2.9

%

 

 

(0.8

)%

 

 

2.2

%

Net income (loss)

 

 

(3.3

)%

 

 

9.8

%

 

 

(1.9

)%

 

 

7.3

%

 

20


 

Net Sales

 

 

 

Three Months Ended

 

 

Percentage

Change

 

 

Six Months Ended

 

 

Percentage

Change

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

2020 vs. 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

 

2020 vs. 2019

 

ICLs

 

$

30,728

 

 

$

34,432

 

 

 

(10.8

)%

 

$

60,068

 

 

$

62,218

 

 

 

(3.5

)%

Other product sales

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

IOLs

 

 

2,561

 

 

 

3,874

 

 

 

(33.9

)%

 

 

6,555

 

 

 

7,891

 

 

 

(16.9

)%

Other surgical products

 

 

1,905

 

 

 

1,358

 

 

 

40.3

%

 

 

3,758

 

 

 

2,138

 

 

 

75.8

%

Total other product sales

 

 

4,466

 

 

 

5,232

 

 

 

(14.6

)%

 

 

10,313

 

 

 

10,029

 

 

 

2.8

%

Net sales

 

$

35,194

 

 

$

39,664

 

 

 

(11.3

)%

 

$

70,381

 

 

$

72,247

 

 

 

(2.6

)%

 

Net sales for the three months ended July 3, 2020 were $35.2 million, a decrease of 11% from $39.7 million reported during the same period of 2019.  The decrease in net sales was due to decreases in ICL sales of $3.7 million and other product sales of $0.8 million.  

Net sales for the six months ended July 3, 2020 were $70.4 million, a decrease of 3% from $72.2 million reported during the same period of 2019.  The decrease in net sales was due to a decrease in ICL sales of $2.2 million, partially offset by an increase in other product sales of $0.3 million.

Total ICL sales for the three months ended July 3, 2020 were $30.7 million, a decrease of 11% from $34.4 million reported for the same period of 2019, with unit decrease of 3%. The Europe, Middle East, Africa and Latin America region sales decreased 30% with unit decrease of 31%.  The North America region sales decreased 55%, with unit decrease of 56%.  The decrease in both these regions were impacted by the COVID-19 pandemic when markets started to reopen in mid-May/early June.  The APAC region sales decreased by 2%, with unit growth up 5% due to unit growth in Japan up 39%, Korea up 16% and China up 6%. ICL sales represented 87.3% and 86.8% of our total sales for the three months ended July 3, 2020 and June 28, 2019, respectively.

Total ICL sales for the six months ended July 3, 2020 were $60.1 million, a 4% decrease from $62.2 million reported for the same period of 2019, with unit growth up 2%. The Europe, Middle East, Africa and Latin America region sales and units decreased 17%.  The North America region sales and units decreased 32%.  The decrease in both these regions were impacted by the COVID-19 pandemic when markets started to reopen in mid-May/early June.  The APAC region sales increased by 3%, with unit growth up 8% due to unit growth in Japan up 58%, Korea up 15% and China up 7%.  ICL sales represented 85.3% and 86.1% of our total sales for the six months ended July 3, 2020 and June 28, 2019, respectively.

Other product sales, including IOLs were $4.5 million for the three months ended July 3, 2020, a decrease of 15% from $5.2 million reported for the same period of 2019.  The decrease is due to a decrease in IOL sales, partially offset by an increase in preloaded injector part sales to a third-party manufacturer for product they sell to their customers.  Other product sales were $10.3 million for the six months ended July 3, 2020, an increase of 3% from $10.0 million reported for the same period of 2019.  The increase is due to an increase in preloaded injector part sales to a third-party manufacturer for product they sell to their customers, offset by a decrease in IOL sales.  Other product sales represented 12.7% and 13.2% of our total sales for the three months ended July 3, 2020 and June 28, 2019, respectively, and represented 14.7% and 13.9% of our total sales for the six months ended July 3, 2020 and June 28, 2019, respectively.

Gross Profit

 

 

 

Three Months Ended

 

 

Percentage

Change

 

 

Six Months Ended

 

 

Percentage

Change

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

2020 vs. 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

 

2020 vs. 2019

 

Gross profit

 

$

24,430

 

 

$

29,899

 

 

 

(18.3

)%

 

$

49,190

 

 

$

54,079

 

 

 

(9.0

)%

Gross margin

 

 

69.4

%

 

 

75.4

%

 

 

 

 

 

 

69.9

%

 

 

74.9

%

 

 

 

 

 

Gross profit for the three months ended July 3, 2020 was $24.4 million, an 18.3% decrease compared to the $29.9 million reported for the same period of 2019.  Gross profit margin decreased to 69.4% of revenue for the three months ended July 3, 2020 compared to 75.4% of revenue for the three months ended June 28, 2019, due to geographic sales mix, $1.0 million in expenses related to the COVID-19 manufacturing pause from April 4 through April 27, 2020, period costs associated with the manufacturing expansion projects, and increased mix of injector part sales which carry a lower margin.  

21


 

Gross profit for the six months ended July 3, 2020 was $49.2 million, a 9.0% decrease compared to the $54.1 million reported for the same period of 2019.  Gross profit margin decreased to 69.9% of revenue for the six months ended July 3, 2020 compared to 74.9% of revenue for the three months ended June 28, 2019, due primarily to geographic sales mix, $1.2 million in expenses related to the COVID-19 manufacturing pause from March 17 through April 27, 2020, period costs associated with the manufacturing expansion projects and increased mix of injector part sales which carry a lower margin.  

General and Administrative Expense

 

 

 

Three Months Ended

 

 

Percentage

Change

 

 

Six Months Ended

 

 

Percentage

Change

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

2020 vs. 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

 

2020 vs. 2019

 

General and administrative expense

 

$

7,848

 

 

$

7,508

 

 

 

4.5

%

 

$

15,817

 

 

$

14,345

 

 

 

10.3

%

Percentage of sales

 

 

22.3

%

 

 

18.9

%

 

 

 

 

 

 

22.5

%

 

 

19.9

%

 

 

 

 

General and administrative expenses for the three months ended July 3, 2020 were $7.8 million, a 4.5% increase compared to the $7.5 million reported for the same period of 2019.  General and administrative expenses for the six months ended July 3, 2020 were $15.8 million, a 10.3% increase compared to the $14.3 million reported for the same period of 2019. The increase in general and administrative expenses for both periods was due to an increase in headcount and salary-related expenses, partially offset by a decrease in variable compensation and travel expenses, and for the six months also due to increased tax consulting and facilities costs.

Marketing and Selling Expense

 

 

 

Three Months Ended

 

 

Percentage

Change

 

 

Six Months Ended

 

 

Percentage

Change

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

2020 vs. 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

 

2020 vs. 2019

 

Marketing and selling expense

 

$

10,326

 

 

$

11,682

 

 

 

(11.6

)%

 

$

21,354

 

 

$

21,825

 

 

 

(2.2

)%

Percentage of sales

 

 

29.3

%

 

 

29.5

%

 

 

 

 

 

 

30.3

%

 

 

30.2

%

 

 

 

 

Marketing and selling expenses for the three months ended July 3, 2020 were $10.3 million, a 11.6% decrease compared to the $11.7 million reported for the same period of 2019.  The decrease in marketing and selling expenses was due to decreased trade show expenses and travel expenses, partially offset by increased advertising and promotional activities.

Marketing and selling expenses for the six months ended July 3, 2020 were $21.4 million, a 2.2% decrease compared to the $21.8 million reported for the same period of 2019.  The decrease in marketing and selling expenses was due to decreased trade show expenses and travel expenses, partially offset by increased advertising, promotional activities and salary-related expenses.

Research and Development Expense

 

 

 

Three Months Ended

 

 

Percentage

Change

 

 

Six Months Ended

 

 

Percentage

Change

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

2020 vs. 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

 

2020 vs. 2019

 

Research and development expense

 

$

7,311

 

 

$

6,098

 

 

 

19.9

%

 

$

14,209

 

 

$

11,733

 

 

 

21.1

%

Percentage of sales

 

 

20.8

%

 

 

15.4

%

 

 

 

 

 

 

20.2

%

 

 

16.3

%

 

 

 

 

Research and development expenses for the three months ended July 3, 2020 were $7.3 million, a 19.9% increase compared to the $6.1 million reported for the same period of 2019. Research and development expenses for the six months ended July 3, 2020 were $14.2 million, a 21.1% increase compared to the $11.7 million reported for the same period of 2019.  The increase in research and development expenses for both periods was primarily due to an increase in expenses related to clinical expenses associated with our EVO clinical trial in the U.S., and increased headcount and salary-related expenses, partially offset by variable compensation and travel expense.  

22


 

Other Income (Expense), Net

 

 

Three Months Ended

 

 

Percentage

Change

 

 

Six Months Ended

 

 

Percentage

Change

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

2020 vs. 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

 

2020 vs. 2019

 

Other income, net

 

$

439

 

 

$

434

 

 

 

1.2

%

 

$

282

 

 

$

725

 

 

 

(61.1

)%

Percentage of sales

 

 

1.2

%

 

 

1.1

%

 

 

 

 

 

 

0.4

%

 

 

1.0

%

 

 

 

 

 

 

*

Denotes change is greater than +100%.

Other income, net for the three months ended July 3, 2020 was $0.4 million, comparable to that reported for the same period of 2019.  Other income, net for the six months ended July 3, 2020 was $0.3 million compared to other income of $0.7 million reported for the same period of 2019.  The decrease in other income, net for the six months was due to decreases in interest income, as a result of lower interest rates, and royalty income, which was impacted by COVID-19 pandemic, partially offset by a decrease in foreign exchange losses (primarily the euro).  

Income Taxes

 

 

 

Three Months Ended

 

 

Percentage

Change

 

 

Six Months Ended

 

 

Percentage

Change

 

 

 

July 3, 2020

 

 

June 28, 2019

 

 

2020 vs. 2019

 

 

July 3, 2020

 

 

June 28, 2019

 

 

2020 vs. 2019

 

Income tax provision (benefit)

 

$

556

 

 

$

1,131

 

 

 

(50.8

)%

 

$

(602

)

 

$

1,620

 

 

 

—*

 

 

 

*

Denotes change is greater than +100%.

We recorded income taxes of $0.6 million and $1.1 million for the three months ended July 3, 2020 and June 28, 2019, respectively, primarily due to pre-tax income generated in certain foreign jurisdictions.  Also for the three months ended June 28, 2019 withholding taxes on foreign operations.  We recorded an income tax benefit of $0.6 million for the six months ended July 3, 2020 due to the income tax benefit from the release of our U.S. valuation allowances, offset by income tax expense from profits generated by our foreign operations.  We recorded income taxes of $1.6 million for the six months ended June 28, 2019 primarily due to pre-tax income generated in certain foreign jurisdictions and withholding taxes on foreign operations.  In the fourth quarter of fiscal year 2019, we reversed all previously recorded withholding taxes recorded for 2019, at which time we formed STAAR Surgical UK Limited as a holding company for our foreign operations.  Based on the current tax treaties between the U.S., United Kingdom and Switzerland, we will no longer accrue for Switzerland withholding taxes on foreign earnings after fiscal 2018 (see also Note 10 in our fiscal 2019 Form 10-K for more information).  We have no unrecognized tax benefits pertaining to any uncertain tax positions as of any period presented.   

ASC 740 requires that a valuation allowance be established when it is more likely than not that all or a portion of a deferred tax asset may not be realizable.  As further described in Notes 1 and 10 of our fiscal 2019 Form 10-K, under the “incremental cash tax savings approach,” we recorded a valuation release of $3.0 million and $0.4 million against federal and certain states deferred tax assets, respectively.  During the six months ended July 3, 2020, we revised our global forecasts as a result of COVID-19, and released an additional $1.4 million of valuation allowance.  As of July 3, 2020, we released approximately $4.9 million of valuation allowance on our deferred tax assets in the U.S. jurisdiction utilizing the incremental cash tax savings approach.  The ultimate realization of deferred tax assets is dependent upon future generation of income during the periods in which temporary differences representing net future deductible amounts become deductible. We considered the projected future income, tax planning strategies and all other available evidence both positive and negative, as well as results of recent operations in making this assessment.    In applying the incremental cash tax savings approach, we will continue to maintain a valuation allowance on the balance of the Company’s net U.S. deferred tax assets of $36.5 million.

Liquidity and Capital Resources

We believe that current cash, cash equivalents and future cash flow from operating activities will be sufficient to meet our anticipated cash needs, including working capital needs, capital expenditures and contractual obligations for at least 12 months from the issuance date of the financial statements included in this quarterly report. We have experienced some delays in payments on accounts receivable as a result of the COVID-19 pandemic but expect this to improve during the third quarter of 2020 as our customers resume elective refractive surgery. This has had a temporary impact on our working capital.  However, at this time we are unaware of any impairment of assets resulting from the COVID19 pandemic.  The Company did not apply for or require financing available under the Coronavirus Aid, Relief, and Economic Security “CARES” Act and

23


 

does not expect to do so given the strength of our balance sheet.  Our financial condition at July 3, 2020 and January 3, 2020 included the following (in millions):

 

 

 

July 3, 2020

 

 

January 3, 2020

 

 

2020 vs. 2019

 

Cash and cash equivalents

 

$

116.3

 

 

$

120.0

 

 

$

(3.7

)

Current assets

 

$

182.5

 

 

$

174.7

 

 

$

7.8

 

Current liabilities

 

 

31.6

 

 

 

34.5

 

 

 

(2.9

)

Working capital

 

$

150.9

 

 

$

140.2

 

 

$

10.7

 

 

We invest the net proceeds in short-term interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.  Additionally, at July 3, 2020, we have a line of credit with a Japanese lender, in the amount of $1.3 million, with $3.3 million of availability and a line of credit with a Swiss lender, in the amount of $1.1 million, which is fully available for borrowing.

Net cash used in operating activities was $8.2 million for the six months ended July 3, 2020 compared to net cash provided by operating activities of $4.2 million for the six months ended June 28, 2019.  Net cash used in operating activities for the six months ended July 3, 2020, consisted of $14.7 million in working-capital changes and a $1.3 million net loss, offset by $7.8 in non-cash items.  The change in net cash used in operating activities during the six months ended July 3, 2020 was due to a decrease in net working capital of $5.0 million, a decrease of $0.8 million in non-cash items and the net loss of $1.3 million during the six months ended July 3, 2020 compared to net income of $5.3 million during the six months ended June 28, 2019.

Net cash used in investing activities was $4.2 million and $4.6 million for the six months ended July 3, 2020 and June 28, 2019, respectively, and relate primarily to the acquisition of property, plant, and equipment.  

Net cash provided by financing activities was $8.7 million for the six months ended July 3, 2020 compared to net cash used in financing activities of $0.6 million for the six months ended June 28, 2019.  Net cash provided by financing activities for the six months ended July 3, 2020 consisted of $9.6 million of proceeds from the exercise of stock options, offset by $0.5 million repayment on the Japan line of credit and $0.3 million repayment of finance lease obligations.  

Credit Facilities and Commitments

Lines of Credit and Leases

See Notes 7 and 8 of the accompanying Condensed Consolidated Financial Statements.

Covenant Compliance

The Company is in compliance with the covenants of its credit facilities as of July 3, 2020.

Employment Agreements

The Company’s Chief Executive Officer entered into an employment agreement with the Company, effective March 1, 2015.  She and certain officers have as provisions of their agreements certain rights, including continuance of cash compensation and benefits, upon a “change in control,” which may include an acquisition of substantially all of its assets, or termination “without cause or for good reason” as defined in the employment agreements.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, as that term is defined in the rules of the SEC, that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

During the six months ended July 3, 2020, there have been no material changes in the Company’s qualitative and quantitative market risk since the disclosure in the Company’s Annual Report on Form 10-K for the year ended January 3, 2020.

24


 

ITEM 4.

CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our CEO and CFO, of the effectiveness of the design and operation of the disclosure controls and procedures of the Company.  Based on that evaluation, our CEO and CFO concluded, as of the end of the period covered by this quarterly report on Form 10-Q, that our disclosure controls and procedures were effective.  For purposes of this statement, the term “disclosure controls and procedures” means controls and other procedures of the Company that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act (15 U.S.C. 78a et seq.) is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our management, including the CEO and the CFO, do not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud or material errors. An internal control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations on all internal control systems, our internal control system can provide only reasonable assurance of achieving its objectives and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of internal control is also based in part upon certain assumptions about the likelihood of future events, and can provide only reasonable, not absolute, assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in circumstances, or the degree of compliance with the policies and procedures may deteriorate.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended July 3, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1.

From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of business.  These legal proceedings and other matters may relate to, among other things, contractual rights and obligations, employment matters, or claims of product liability.  STAAR maintains insurance coverage for various matters, including product liability and certain securities claims.  While we do not believe that any of the claims known is likely to have a material adverse effect on our financial condition or results of operations, new claims or unexpected results of existing claims could lead to significant financial harm.

ITEM 1A.

RISK FACTORS

Our short and long-term success is subject to many factors that are beyond our control. Investors and prospective investors should consider carefully information contained in this report and the risks and uncertainties described in “Part I—Item 1A—Risk Factors” of the Company’s Form 10-K for the fiscal year ended January 3, 2020 and in “Part II—Item 1A—Risk Factors” of the Company’s Form 10-Q for the three months ended April 3, 2020. Such risks and uncertainties could materially adversely affect our business, financial condition or operating results.  

ITEM 4.

MINE SAFETY DISCLOSURES

Not Applicable.

25


 

ITEM 5.

OTHER INFORMATION

Effective May 1, 2020, the Compensation Committee of the Board of Directors, as Administrator of STAAR’s Equity Incentive Plan, approved an amendment to Section 12.5 of STAAR’s Amended and Restated Omnibus Equity Incentive Plan to permit discretionary acceleration of vesting of equity awards granted to a non-employee director in the event of a Termination of Service, as defined by the Plan, after serving a minimum of at least one-half of the relevant term under any Award Agreement, as defined by the Plan.

ITEM 6.

EXHIBITS

 

   3.1

Amended and Restated Certificate of Incorporation.(1)

 

 

   3.2

Amended and Restated Bylaws.(2)

 

 

   4.1

Form of Certificate for Common Stock, par value $0.01 per share.(3)

 

 

 †4.2

Amended and Restated Omnibus Equity Incentive Plan.*

 

 

 †10.38

Letter of the Company dated June 30, 2020 to Patrick Williams, Chief Financial Officer, regarding compensation.*

 

 

 31.1

Certifications Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

 

 

 31.2

Certifications Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

 

 

 32.1

Certification Pursuant to 18 U.S.C. Section 1350, Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. **

 

 

 101

Financial statements from the quarterly report on Form 10-Q of STAAR Surgical Company for the quarter ended July 3, 2020 formatted in Inline Extensible Business Reporting Language (iXBRL), are filed herewith and include: (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Income, (iii) the Condensed Consolidated Statements of Comprehensive Income, (iv) the Condensed Consolidated Statements of Stockholders’ Equity, (v) the Condensed Consolidated Statements of Cash Flows, and (vi) the Notes to Condensed Consolidated Financial Statements tagged as blocks of text.*

 

 

 104

The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended July 3, 2020, has been formatted in Inline XBRL with applicable taxonomy extension information contained in Exhibit 101.

 

(1)

Incorporated by reference to Appendix 2 of the Company’s Proxy Statement on Form DEF 14A as filed with the Commission on April 13, 2018

(2)

Incorporated by reference to Appendix 3 of the Company’s Proxy Statement on Form DEF 14A as filed with the Commission on April 13, 2018.

(3)

Incorporated by reference to Exhibit 4.1 to Amendment No. 1 to the Company’s Registration Statement on Form 8‑A/A as filed with the Commission on April 18, 2003.

*

Filed herewith.

**

Furnished herewith.

Management contract or compensatory plan.

26


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

STAAR SURGICAL COMPANY

 

 

 

 

 

 

Dated:

 

August 5, 2020

By:

 

/s/ PATRICK F. WILLIAMS

 

 

 

 

 

Patrick F. Williams

 

 

 

 

 

Chief Financial Officer

 

 

 

 

 

(on behalf of the Registrant and as its principal financial officer)

 

27

Exhibit 4.2

 

STAAR SURGICAL COMPANY
AMENDED AND RESTATED OMNIBUS EQUITY INCENTIVE PLAN

 

ARTICLE 1.

PURPOSE

The purpose of the STAAR Surgical Company Amended and Restated Omnibus Equity Incentive Plan (as it may be amended or restated from time to time, the “Plan”) is to promote the success and enhance the value of STAAR Surgical Company (the “Company”) by linking the individual interests of the members of the Board, Employees, and Consultants to those of Company stockholders and by providing such individuals with an incentive for outstanding performance. The Plan is further intended to provide flexibility to the Company in its ability to motivate, attract, and retain the services of members of the Board, Employees, and Consultants upon whose judgment, interest, and special effort the successful conduct of the Company’s operation is largely dependent.  This Plan constitutes an amendment and restatement of the STAAR Surgical Company Amended and Restated 2003 Omnibus Equity Incentive Plan (the “Original Plan”), which was last approved by the Company’s stockholders on June 14, 2018.

ARTICLE 2.

DEFINITIONS AND CONSTRUCTION

Wherever the following terms are used in the Plan they shall have the meanings specified below, unless the context clearly indicates otherwise. The singular pronoun shall include the plural where the context so indicates.

2.1Administrator” shall mean the entity that conducts the general administration of the Plan as provided in Article 12. With reference to the duties of the Committee under the Plan which have been delegated to one or more persons pursuant to Section 12.7, or as to which the Board has assumed, the term “Administrator” shall refer to such person(s) unless the Committee or the Board has revoked such delegation or the Board has terminated the assumption of such duties.

2.2Applicable Accounting Standards” shall mean Generally Accepted Accounting Principles in the United States, International Financial Reporting Standards or such other accounting principles or standards as may apply to the Company’s financial statements under United States federal securities laws from time to time.

2.3Applicable Law” shall mean any applicable law, including without limitation: (a) provisions of the Code, the Securities Act, the Exchange Act and any rules or regulations thereunder; (b) corporate, securities, tax or other laws, statutes, rules, requirements or regulations, whether federal, state, local or foreign; and (c) rules of any securities exchange or automated quotation system on which the Shares are listed, quoted or traded.

 


 

2.4Award” shall mean an Option, a Stock Appreciation Right, a Restricted Stock award, a Restricted Stock Unit award, an Other Stock or Cash Based Award or a Dividend Equivalent award, which may be awarded or granted under the Plan.

2.5Award Agreement” shall mean any written notice, agreement, terms and conditions, contract or other instrument or document evidencing an Award, including through electronic medium, which shall contain such terms and conditions with respect to an Award as the Administrator shall determine consistent with the Plan.

2.6Award Limit” shall mean with respect to Awards that shall be payable in Shares or in cash, as the case may be, the respective limit set forth in Section 3.2.

2.7Board” shall mean the Board of Directors of the Company.

2.8Change in Control” shall mean the occurrence of any one (or more) of the following events:

(a)Any person, including a group as defined in Section 13(d)(3) of the Exchange Act, becomes the beneficial owner of stock of the Company with respect to which fifty percent (50%) or more of the total number of votes for the election of the Board may be cast;

(b)The Incumbent Directors cease for any reason to constitute a majority of the Board;

(c)The Company consummates an agreement providing either for a transaction in which the Company will cease to be an independent publicly owned corporation or for a sale or other disposition of all or substantially all the assets of the Company; or

(d)An acquisition in a single or series of related transactions, including without limitation a tender offer or exchange offer, by any person or related group of persons (other than the Company or by a Company-sponsored employee benefit plan), of beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) of securities possessing more than fifty percent (50%) of the total combined voting power of the Company's outstanding securities.

Notwithstanding the foregoing, the following transactions shall not constitute a Change in Control for purposes of the Plan: (i) any acquisition by the Company or any of its Subsidiaries; or (ii) any transaction (x) which results in the Company’s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company’s assets or otherwise succeeds to the business of the Company (the Company or such person, the “Successor Entity”)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity’s outstanding voting securities immediately after the transaction; (y) after which no person or group beneficially owns voting securities representing 50% or more of the combined voting power of the Successor Entity, provided, however, that no person or group shall be treated for purposes of this clause (y) as beneficially owning 50% or more of the combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the consummation of the transaction and (z) any transaction after which

 


 

at least a majority of the members of the board of directors (or the analogous governing body) of the Successor Entity were Board members at the time of the Board's approval of the execution of the initial agreement providing for such transaction.

Further notwithstanding the foregoing, if a Change in Control constitutes a payment event with respect to any Award (or any portion of an Award) that provides for the deferral of compensation that is subject to Section 409A, to the extent required to avoid the imposition of additional taxes under Section 409A, the transaction or event described in subsection (a), (b), (c) or (d) with respect to such Award (or portion thereof) shall only constitute a Change in Control for purposes of the payment timing of such Award if such transaction also constitutes a “change in control event,” as defined in Treasury Regulation Section 1.409A-3(i)(5).

2.9Code” shall mean the Internal Revenue Code of 1986, as amended from time to time, together with the regulations and official guidance promulgated thereunder, whether issued prior or subsequent to the grant of any Award.

2.10Committee” shall mean the Compensation Committee of the Board, or another committee or subcommittee of the Board or the Compensation Committee of the Board described in Article 12 hereof.

2.11Common Stock” shall mean the common stock of the Company, par value $0.01 per share.

2.12Company” shall have the meaning set forth in Article 1.

2.13Consultant” shall mean any consultant or adviser engaged to provide services to the Company or any Subsidiary who qualifies as a consultant or advisor under the applicable rules of the Securities and Exchange Commission for registration of shares on a Form S-8 Registration Statement.

2.14Covered Employee” shall mean any Employee who is, or could become, a “covered employee” within the meaning of Section 162(m) of the Code.

2.15Director” shall mean a member of the Board, as constituted from time to time.

2.16Director Limit” shall have the meaning set forth in Section 4.6.

2.17Dividend Equivalent” shall mean a right to receive the equivalent value (in cash or Shares) of dividends paid on Shares, awarded under Section 10.2.

2.18DRO” shall mean a “domestic relations order” as defined by the Code or Title I of the Employee Retirement Income Security Act of 1974, as amended from time to time, or the rules thereunder.

2.19Effective Date” shall mean the date the Plan is adopted by the Board, subject to approval of the Plan by the Company’s stockholders.

 


 

2.20Eligible Individual” shall mean any person who is an Employee, a Consultant or a Non-Employee Director, as determined by the Administrator.

2.21Employee” shall mean any officer or other employee (as determined in accordance with Section 3401(c) of the Code and the Treasury Regulations thereunder) of the Company or of any Subsidiary.

2.22Equity Restructuring” shall mean a nonreciprocal transaction between the Company and its stockholders, such as a stock dividend, stock split, spin-off, rights offering or recapitalization through a large, nonrecurring cash dividend, that affects the number or kind of Shares (or other securities of the Company) or the share price of Common Stock (or other securities) and causes a change in the per-share value of the Common Stock underlying outstanding Awards.

2.23Exchange Act” shall mean the Securities Exchange Act of 1934, as amended from time to time.

2.24Expiration Date” shall have the meaning given to such term in Section 13.1(c).

2.25Fair Market Value” shall mean, as of any given date, the value of a Share determined as follows:

(a)If the Common Stock is (i) listed on any established securities exchange (such as the New York Stock Exchange, the NASDAQ Capital Market, the NASDAQ Global Market and the NASDAQ Global Select Market), (ii) listed on any national market system or (iii) quoted or traded on any automated quotation system, its Fair Market Value shall be the closing sales price for a Share as quoted on such exchange or system for such date or, if there is no closing sales price for a Share on the date in question, the closing sales price for a Share on the last preceding date for which such quotation exists, as reported in The Wall Street Journal or such other source as the Administrator deems reliable;

(b)If the Common Stock is not listed on an established securities exchange, national market system or automated quotation system, but the Common Stock is regularly quoted by a recognized securities dealer, its Fair Market Value shall be the mean of the high bid and low asked prices for such date or, if there are no high bid and low asked prices for a Share on such date, the high bid and low asked prices for a Share on the last preceding date for which such information exists, as reported in The Wall Street Journal or such other source as the Administrator deems reliable; or

(c)If the Common Stock is neither listed on an established securities exchange, national market system or automated quotation system nor regularly quoted by a recognized securities dealer, its Fair Market Value shall be established by the Administrator in good faith.

2.26“Full Value Award” shall mean any Award granted under the Plan other than an Option or a Share Appreciation Right and that is settled by the issuance of Shares.

2.27Greater Than 10% Stockholder” shall mean an individual then owning (within the meaning of Section 424(d) of the Code) more than 10% of the total combined voting power of

 


 

all classes of stock of the Company or any subsidiary corporation (as defined in Section 424(f) of the Code) or parent corporation thereof (as defined in Section 424(e) of the Code).

2.28Holder” shall mean a person who has been granted an Award.

2.29Incentive Stock Option” shall mean an Option that is intended to qualify as an incentive stock option and conforms to the applicable provisions of Section 422 of the Code.

2.30Incumbent Directors” shall mean for any period of 12 consecutive months, commencing with this Plan’s Effective Date, individuals who, at the beginning of such period, constitute the Board together with any new Director(s) (other than a Director designated by a person who shall have entered into an agreement with the Company to effect a transaction described in Section 2.8(a), (c) or (d) whose election or nomination for election to the Board was approved by a vote of at least a majority (either by a specific vote or by approval of the proxy statement of the Company in which such person is named as a nominee for Director without objection to such nomination) of the Directors then still in office who either were Directors at the beginning of the 12-month period or whose election or nomination for election was previously so approved.  No individual initially elected or nominated as a director of the Company as a result of an actual or threatened election contest with respect to Directors or as a result of any other actual or threatened solicitation of proxies by or on behalf of any person other than the Board shall be an Incumbent Director.

2.31Non-Employee Director” shall mean a Director of the Company who is not an Employee.

2.32Non-Qualified Stock Option” shall mean an Option that is not an Incentive Stock Option or which is designated as an Incentive Stock Option but does not meet the applicable requirements of Section 422 of the Code.

2.33Option” shall mean a right to purchase Shares at a specified exercise price, granted under Article 6. An Option shall be either a Non-Qualified Stock Option or an Incentive Stock Option; provided, however, that Options granted to Non-Employee Directors and Consultants shall only be Non-Qualified Stock Options.

2.34Option Term” shall have the meaning set forth in Section 6.4.

2.35Organizational Documents” shall mean, collectively, (a) the Company’s articles of incorporation, certificate of incorporation, bylaws or other similar organizational documents relating to the creation and governance of the Company, and (b) the Committee’s charter or other similar organizational documentation relating to the creation and governance of the Committee.

2.36Original Plan” shall have the meaning set forth in Article 1.

2.37Other Stock or Cash Based Award” shall mean a cash payment, cash bonus award, stock payment, stock bonus award, performance award or incentive award that is paid in cash, Shares or a combination of both, awarded under Section 10.1, which may include, without limitation, deferred stock, deferred stock units, performance awards, retainers, committee fees, and meeting-based fees.

 


 

2.38Performance-Based Compensation shall mean any compensation that is intended to qualify as performance-based compensation as described in Section 162(m)(4)(C) of the Code.

2.39Performance Criteria” shall mean the criteria (and adjustments) that the Administrator selects for an Award for purposes of establishing the Performance Goal or Performance Goals for a Performance Period, determined as follows:

(a)The Performance Criteria that shall be used to establish Performance Goals are limited to the following: (i) revenue, (ii) earnings, or earnings before interest, taxes, depreciation and amortization, or EBITDA, (iii) earnings per share, (iv) stock price, (v) operating cash flow, (vi) net income, (vii) profit margins, operating margins, gross margins or cash margins, (viii) revenue growth, (ix) pre- or after-tax income (before or after allocations of corporate overhead and bonuses), (x) return on equity, (xi) total shareholder return, (xii) return on assets or net assets, (xiii) appreciation in and/or maintenance of the price of the Common Stock, (xiv) market share, (xv) gross profits, (xvi) economic value-added models or equivalent metrics, (xvii) comparisons with various stock market indices, (xviii) reductions in costs, (xix) cash flow or cash flow per share, (xx) return on capital (including return on total capital or return on invested capital), (xxi) cash flow return on investment, (xxii) improvement in or attainment of expense levels or working capital levels, (xxiii) year-end cash, (xxiv) debt reductions, (xxv) stockholder equity, (xxvi) regulatory or litigation achievements, (xxvii) implementation, completion or attainment of measurable objectives with respect to business development, new products or services, budgets, regulatory or business risks, acquisitions, divestitures or recruiting and maintaining personnel, (xxviii) earnings, (xxix) expenses, (xxx) cost of goods sold, (xxxi) working capital, (xxxii) price/earnings ratio, (xxxiii) debt or debt-to-equity, (xxxiv) accounts receivable, (xxxv) writeoffs, (xxxvi) assets, (xxxvii) liquidity, (xxxviii) operations, (xxxix) research or related milestones, (xl) intellectual property (e.g., patents), (xli) product development, (xlii) information technology, (xliii) financings, (xliv) product quality control, (xlv) management, (xlvi) human resources, (xlvii) corporate governance, (xlviii) compliance program, (xlix) internal controls, (xlxi) policies and procedures, (xlxii) accounting and reporting, (xlxiii) strategic alliances, (xlxiv) licensing and partnering, (xlxv) site, plant or building development, (xlxvi) business initiatives; (xlxviii) investments, and/or (xlxviii) any combination of the foregoing, any of which may be measured either in absolute terms, or changes in growth or reduction, or as compared to any increase or decrease or as compared to results of a peer group or index. Such Performance Goals also may be based solely by reference to the Company’s performance or the performance of a Subsidiary, division, business segment or business unit of the Company, or based upon the relative performance of other companies or upon comparisons of any of the indicators of performance relative to other companies.

(b)The Administrator may, in its sole discretion, provide that one or more objectively determinable adjustments shall be made to one or more of the Performance Goals. Such adjustments may include one or more of the following: (i) items related to a change in or provisions under tax law, accounting principles or other such laws or provisions affecting reported results; (ii) items relating to financing activities; (iii) expenses for restructuring or productivity initiatives; (iv) other non-operating items; (v) items related to reorganizations or restructuring programs or divestitures or acquisitions; (vi) items attributable to the business operations of any entity acquired by the Company during the Performance Period; (vii) items related to asset write-

 


 

downs or the disposal of a business or segment of a business; (viii) items related to discontinued operations that do not qualify as a segment of a business under U.S. Generally Accepted Accounting Principles; (ix) items attributable to any stock dividend, stock split, combination or exchange of shares occurring during the Performance Period; (x) any other items of significant income or expense which are determined to be appropriate adjustments; (xi) items relating to unusual or extraordinary corporate transactions, events or developments, (xii) items related to amortization of acquired intangible assets; (xiii) items that are outside the scope of the Company's core, on-going business activities; (xiv) items relating to any other unusual or nonrecurring events or changes in applicable laws, accounting principles or business conditions and/or items of gain, loss or expense determined to be extraordinary or unusual in nature or infrequent in occurrence; (xv) litigation or claim judgments or settlements; (xvi) items related to acquired in-process research and development; (xvii) items relating to changes in tax laws; (xviii) items relating to major licensing or partnership arrangements; (xix) items relating to asset impairment charges; (xx) items attributable to expenses incurred in connection with a reduction in force or early retirement initiative; or (xxi) items relating to foreign exchange or currency transactions and/or fluctuations. For all Awards intended to qualify as performance-based compensation, such determinations shall be made within the time prescribed by, and otherwise in compliance with, Section 162(m) of the Code.

2.40Performance Goals” shall mean, for a Performance Period, one or more goals established in writing by the Administrator for the Performance Period based upon one or more Performance Criteria. Depending on the Performance Criteria used to establish such Performance Goals, the Performance Goals may be expressed in terms of overall Company performance or the performance of a Subsidiary, division, business unit, or an individual.

2.41Performance Period” shall mean one or more periods of time, which may be of varying and overlapping durations, as the Administrator may select, over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Holder’s right to, vesting of, and/or the payment in respect of, an Award.

2.42Permitted Transferee” shall mean, with respect to a Holder, any “family member” of the Holder, as defined in the General Instructions to Form S-8 Registration Statement under the Securities Act (or any successor form thereto), or any other transferee specifically approved by the Administrator after taking into account Applicable Law.

2.43Plan” shall have the meaning set forth in Article 1.

2.44Program” shall mean any program adopted by the Administrator pursuant to the Plan containing the terms and conditions intended to govern a specified type of Award granted under the Plan and pursuant to which such type of Award may be granted under the Plan.

2.45Restricted Stock” shall mean Common Stock awarded under Article 8 that is subject to certain restrictions and may be subject to risk of forfeiture or repurchase.

2.46Restricted Stock Units” shall mean the right to receive Shares awarded under Article 9.

 


 

2.47Section 409A” shall mean Section 409A of the Code and the Department of Treasury regulations and other interpretive guidance issued thereunder, including, without limitation, any such regulations or other guidance that may be issued after the Effective Date.

2.48Securities Act” shall mean the Securities Act of 1933, as amended.

2.49Shares” shall mean shares of Common Stock.

2.50Stock Appreciation Right” shall mean an Award entitling the Holder (or other person entitled to exercise pursuant to the Plan) to exercise all or a specified portion thereof (to the extent then exercisable pursuant to its terms) and to receive from the Company an amount determined by multiplying the difference obtained by subtracting the exercise price per share of such Award from the Fair Market Value on the date of exercise of such Award by the number of Shares with respect to which such Award shall have been exercised, subject to any limitations the Administrator may impose.

2.51SAR Term” shall have the meaning set forth in Section 6.4.

2.52Subsidiary” shall mean any entity (other than the Company), whether domestic or foreign, in an unbroken chain of entities beginning with the Company if each of the entities other than the last entity in the unbroken chain beneficially owns, at the time of the determination, securities or interests representing at least fifty percent (50%) of the total combined voting power of all classes of securities or interests in one of the other entities in such chain.

2.53Substitute Award” shall mean an Award granted under the Plan in connection with a corporate transaction, such as a merger, combination, consolidation or acquisition of property or stock, in any case, upon the assumption of, or in substitution for, outstanding equity awards previously granted by a company or other entity; provided, however, that in no event shall the term “Substitute Award” be construed to refer to an award made in connection with the cancellation and repricing of an Option or Stock Appreciation Right.

2.54Termination of Service” shall mean:

(a)As to a Consultant, the time when the engagement of a Holder as a Consultant to the Company or a Subsidiary is terminated for any reason, with or without cause, including, without limitation, by resignation, discharge, death or retirement, but excluding terminations where the Consultant simultaneously commences or remains in employment or service with the Company or any Subsidiary.

(b)As to a Non-Employee Director, the time when a Holder who is a Non-Employee Director ceases to be a Director for any reason, including, without limitation, a termination by resignation, failure to be elected, death or retirement, but excluding terminations where the Holder simultaneously commences or remains in employment or service with the Company or any Subsidiary.

(c)As to an Employee, the time when the employee-employer relationship between a Holder and the Company or any Subsidiary is terminated for any reason, including, without limitation, a termination by resignation, discharge, death, disability or retirement; but

 


 

excluding terminations where the Holder simultaneously commences or remains in employment or service with the Company or any Subsidiary.

The Administrator, in its sole discretion, shall determine the effect of all matters and questions relating to any Termination of Service, including, without limitation, whether a Termination of Service has occurred, whether a Termination of Service resulted from a discharge for cause and all questions of whether particular leaves of absence constitute a Termination of Service; provided, however, that, with respect to Incentive Stock Options, unless the Administrator otherwise provides in the terms of any Program, Award Agreement or otherwise, or as otherwise required by Applicable Law, a leave of absence, change in status from an employee to an independent contractor or other change in the employee-employer relationship shall constitute a Termination of Service only if, and to the extent that, such leave of absence, change in status or other change interrupts employment for the purposes of Section 422(a)(2) of the Code and the then-applicable regulations and revenue rulings under said Section. For purposes of the Plan, a Holder’s employee-employer relationship or consultancy relations shall be deemed to be terminated in the event that the Subsidiary employing or contracting with such Holder ceases to remain a Subsidiary following any merger, sale of stock or other corporate transaction or event (including, without limitation, a spin-off).

ARTICLE 3.

SHARES SUBJECT TO THE PLAN

3.1Number of Shares.

(a)Subject to Sections 3.1(b) and 13.2, the aggregate number of Shares which may be issued or transferred pursuant to Awards (including, without limitation, Incentive Stock Options) under the Plan is 18,035,000.  Any Shares distributed pursuant to an Award may consist, in whole or in part, of authorized and unissued Common Stock, treasury Common Stock or Common Stock purchased on the open market. Notwithstanding the foregoing, the aggregate number of Shares available for issuance under the Plan shall be reduced by two Shares for each Share delivered in settlement of any Full Value Award granted on or after the Effective Date.

(b)To the extent all or a portion of an Award is forfeited, expires or such Award or portion thereof is settled for cash (in whole or in part), the Shares counted against the Shares available under the Plan with respect to such Award shall, to the extent of such forfeiture, expiration or cash settlement, again be available for future grants of Awards under the Plan in an amount corresponding to the reduction in the share reserve previously made in accordance with Section 3.1(a) above. Notwithstanding anything to the contrary contained herein, the following Shares shall not be added to the Shares authorized for grant under Section 3.1(a) and will not be available for future grants of Awards: (i) Shares tendered by a Holder or withheld by the Company in payment of the exercise price of an Option; (ii) Shares tendered by the Holder or withheld by the Company to satisfy any tax withholding obligation with respect to any Award; (iii) Shares subject to a Stock Appreciation Right that are not issued in connection with the stock settlement of the stock appreciation right on exercise thereof; and (iv) Shares purchased on the open market with the cash proceeds from the exercise of Options. Any Shares forfeited by the Holder or repurchased by the Company under Section 8.4 at a price not greater than the price originally paid

 


 

by the Holder so that such Shares are returned to the Company will again be available for Awards in an amount corresponding to the reduction in the share reserve previously made in accordance with Section 3.1(a) above. The payment of Dividend Equivalents in cash in conjunction with any outstanding Awards shall not be counted against the shares available for issuance under the Plan. Notwithstanding the provisions of this Section 3.1(b), no Shares may again be optioned, granted or awarded if such action would cause an Incentive Stock Option to fail to qualify as an incentive stock option under Section 422 of the Code.

(c)Substitute Awards shall not reduce the Shares authorized for grant under the Plan, except as may be required by reason of Section 422 of the Code. Additionally, in the event that a company acquired by the Company or any Subsidiary or with which the Company or any Subsidiary combines has shares available under a pre-existing plan approved by its stockholders and not adopted in contemplation of such acquisition or combination, the shares available for grant pursuant to the terms of such pre-existing plan (as adjusted, to the extent appropriate, using the exchange ratio or other adjustment or valuation ratio or formula used in such acquisition or combination to determine the consideration payable to the holders of common stock of the entities party to such acquisition or combination) may be used for Awards under the Plan and shall not reduce the Shares authorized for grant under the Plan; provided that Awards using such available Shares shall not be made after the date awards or grants could have been made under the terms of the pre-existing plan, absent the acquisition or combination, and shall only be made to individuals who were not employed by or providing services to the Company or its Subsidiaries immediately prior to such acquisition or combination.

3.2Limitation on Number of Shares Subject to Awards. Notwithstanding any provision in the Plan to the contrary, and subject to Section 13.2, the maximum aggregate number of Shares with respect to one or more Awards that may be granted to any one person during any calendar year shall be 400,000 and the maximum aggregate amount of cash that may be paid in cash to any one person during any calendar year with respect to one or more Awards payable in cash shall be $2,000,000. To the extent required by Section 162(m) of the Code, Shares subject to Awards which are canceled shall continue to be counted against the Award Limit.

ARTICLE 4.

GRANTING OF AWARDs

4.1Participation. The Administrator may, from time to time, select from among all Eligible Individuals, those to whom an Award shall be granted and shall determine the nature and amount of each Award, which shall not be inconsistent with the requirements of the Plan. Except for any Non-Employee Director’s right to Awards that may be required pursuant to the No Eligible Individual or other Person shall have any right to be granted an Award pursuant to the Plan and neither the Company nor the Administrator is obligated to treat Eligible Individuals, Holders or any other persons uniformly. Participation by each Holder in the Plan shall be voluntary and nothing in the Plan or any Program shall be construed as mandating that any Eligible Individual or other Person shall participate in the Plan.

4.2Award Agreement. Each Award shall be evidenced by an Award Agreement that sets forth the terms, conditions and limitations for such Award as determined by the Administrator

 


 

in its sole discretion (consistent with the requirements of the Plan and any applicable Program). Award Agreements evidencing Incentive Stock Options shall contain such terms and conditions as may be necessary to meet the applicable provisions of Section 422 of the Code.

4.3Limitations Applicable to Section 16 Persons. Notwithstanding any other provision of the Plan, the Plan, and any Award granted or awarded to any individual who is then subject to Section 16 of the Exchange Act, shall be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including Rule 16b‑3 of the Exchange Act and any amendments thereto) that are requirements for the application of such exemptive rule. To the extent permitted by Applicable Law, the Plan and Awards granted or awarded hereunder shall be deemed amended to the extent necessary to conform to such applicable exemptive rule.

4.4At-Will Service. Nothing in the Plan or in any Program or Award Agreement hereunder shall confer upon any Holder any right to continue in the employ of, or as a Director or Consultant for, the Company or any Subsidiary, or shall interfere with or restrict in any way the rights of the Company and any Subsidiary, which rights are hereby expressly reserved, to discharge any Holder at any time for any reason whatsoever, with or without cause, and with or without notice, or to terminate or change all other terms and conditions of employment or engagement, except to the extent expressly provided otherwise in a written agreement between the Holder and the Company or any Subsidiary.

4.5Foreign Holders. Notwithstanding any provision of the Plan or applicable Program to the contrary, in order to comply with the laws in countries other than the United States in which the Company and its Subsidiaries operate or have Employees, Non-Employee Directors or Consultants, or in order to comply with the requirements of any foreign securities exchange or other Applicable Law, the Administrator, in its sole discretion, shall have the power and authority to: (a) determine which Subsidiaries shall be covered by the Plan; (b) determine which Eligible Individuals outside the United States are eligible to participate in the Plan; (c) modify the terms and conditions of any Award granted to Eligible Individuals outside the United States to comply with Applicable Law (including, without limitation, applicable foreign laws or listing requirements of any foreign securities exchange); (d) establish sub-plans and modify exercise procedures and other terms and procedures, to the extent such actions may be necessary or advisable; provided, however, that no such sub-plans and/or modifications shall increase the share limitation contained in Section 3.1, the Award Limit or the Director Limit; and (e) take any action, before or after an Award is made, that it deems advisable to obtain approval or comply with any necessary local governmental regulatory exemptions or approvals or listing requirements of any foreign securities exchange.

4.6Non-Employee Director Awards. Notwithstanding any provision to the contrary in the Plan, the sum of the grant date fair value of equity-based Awards granted to a Non-Employee Director during any calendar year shall not exceed $500,000 (the “Director Limit”).  

 


 

ARTICLE 5.

Provisions Applicable to Awards Intended to Qualify as Performance-Based Compensation

5.1Purpose. The Administrator may, in its sole discretion, (a) determine whether an Award is intended to qualify as Performance-Based Compensation and (b) at any time after any such determination, alter such intent for any or no reason. If the Administrator, in its sole discretion, decides to grant an Award that is intended to qualify as Performance-Based Compensation (other than an Option or Stock Appreciation Right), then the provisions of this Article 5 shall control over any contrary provision contained in the Plan or any applicable Program; provided that, if after such decision the Administrator alters such intention for any reason, the provisions of this Article 5 shall no longer control over any other provision contained in the Plan or any applicable Program. The Administrator, in its sole discretion, may (i) grant Awards to Eligible Individuals that are based on Performance Criteria or Performance Goals or any such other criteria and goals as the Administrator shall establish, but that do not satisfy the requirements of this Article 5 and that are not intended to qualify as Performance-Based Compensation and (ii) subject any Awards intended to qualify as Performance-Based Compensation to additional conditions and restrictions unrelated to any Performance Criteria or Performance Goals (including, without limitation, continued employment or service requirements) to the extent such Awards otherwise satisfy the requirements of this Article 5 with respect to the Performance Criteria and Performance Goals applicable thereto. Unless otherwise specified by the Administrator at the time of grant, the Performance Criteria with respect to an Award intended to be Performance-Based Compensation payable to a Covered Employee shall be determined on the basis of Applicable Accounting Standards.

5.2Procedures with Respect to Performance-Based Awards. To the extent necessary to comply with the requirements of Section 162(m)(4)(C) of the Code, with respect to any Award which is intended to qualify as Performance-Based Compensation, no later than 90 days following the commencement of any Performance Period or any designated fiscal period or period of service (or such earlier time as may be required under Section 162(m) of the Code), the Administrator shall, in writing, (a) designate one or more Eligible Individuals, (b) select the Performance Criteria applicable to the Performance Period, (c) establish the Performance Goals, and amounts of such Awards, as applicable, which may be earned for such Performance Period based on the Performance Criteria, and (d) specify the relationship between Performance Criteria and the Performance Goals and the amounts of such Awards, as applicable, to be earned by each Covered Employee for such Performance Period. Following the completion of each Performance Period, the Administrator shall certify in writing whether and the extent to which the applicable Performance Goals have been achieved for such Performance Period. In determining the amount earned under such Awards, the Administrator (i) shall, unless otherwise provided in an Award Agreement, have the right to reduce or eliminate the amount payable at a given level of performance to take into account additional factors that the Administrator may deem relevant, including the assessment of individual or corporate performance for the Performance Period, but (ii) shall in no event have the right to increase the amount payable for any reason.

5.3Payment of Performance-Based Awards. Unless otherwise provided in the applicable Program or Award Agreement and only to the extent otherwise permitted by Section

 


 

162(m) of the Code, as to an Award that is intended to qualify as Performance-Based Compensation, the Holder must be employed by the Company or a Subsidiary throughout the Performance Period. Unless otherwise provided in the applicable Program or Award Agreement, a Holder shall be eligible to receive payment pursuant to such Awards for a Performance Period only if and to the extent the Performance Goals for such Performance Period are achieved.

5.4Additional Limitations. Notwithstanding any other provision of the Plan and except as otherwise determined by the Administrator, any Award which is granted to an Eligible Individual and is intended to qualify as Performance-Based Compensation shall be subject to any additional limitations set forth in Section 162(m) of the Code or any regulations or rulings issued thereunder that are requirements for qualification as Performance-Based Compensation, and the Plan and the applicable Program and Award Agreement shall be deemed amended to the extent necessary to conform to such requirements.

ARTICLE 6.

granting OF OPTIONS and stock appreciation rights

6.1Granting of Options and Stock Appreciation Rights to Eligible Individuals. The Administrator is authorized to grant Options and Stock Appreciation Rights to Eligible Individuals from time to time, in its sole discretion, on such terms and conditions as it may determine, which shall not be inconsistent with the Plan.

6.2Qualification of Incentive Stock Options. The Administrator may grant Options intended to qualify as Incentive Stock Options only to employees of the Company, any of the Company’s present or future “parent corporations” or “subsidiary corporations” as defined in Sections 424(e) or (f) of the Code, respectively, and any other entities the employees of which are eligible to receive Incentive Stock Options under the Code. No person who qualifies as a Greater Than 10% Stockholder may be granted an Incentive Stock Option unless such Incentive Stock Option conforms to the applicable provisions of Section 422 of the Code. To the extent that the aggregate fair market value of stock with respect to which “incentive stock options” (within the meaning of Section 422 of the Code, but without regard to Section 422(d) of the Code) are exercisable for the first time by a Holder during any calendar year under the Plan, and all other plans of the Company and any parent corporation or subsidiary corporation thereof (as defined in Section 424(e) and 424(f) of the Code, respectively), exceeds $100,000, the Options shall be treated as Non-Qualified Stock Options to the extent required by Section 422 of the Code. The rule set forth in the immediately preceding sentence shall be applied by taking Options and other “incentive stock options” into account in the order in which they were granted and the fair market value of stock shall be determined as of the time the respective options were granted. Any interpretations and rules under the Plan with respect to Incentive Stock Options shall be consistent with the provisions of Section 422 of the Code.  Neither the Company nor the Administrator shall have any liability to a Holder, or any other Person, (a) if an Option (or any part thereof) which is intended to qualify as an Incentive Stock Option fails to qualify as an Incentive Stock Option or (b) for any action or omission by the Company or the Administrator that causes an Option not to qualify as an Incentive Stock Option, including without limitation, the conversion of an Incentive Stock Option to a Non-Qualified Stock Option or the grant of an Option intended as an Incentive

 


 

Stock Option that fails to satisfy the requirements under the Code applicable to an Incentive Stock Option.  

6.3Option and Stock Appreciation Right Exercise Price. The exercise price per Share subject to each Option and Stock Appreciation Right shall be set by the Administrator but shall not be less than 100% of the Fair Market Value of a Share on the date the Option or Stock Appreciation Right, as applicable, is granted (or, as to Incentive Stock Options, on the date the Option is modified, extended or renewed for purposes of Section 424(h) of the Code). In addition, in the case of Incentive Stock Options granted to a Greater Than 10% Stockholder, such price shall not be less than 110% of the Fair Market Value of a Share on the date the Option is granted (or the date the Option is modified, extended or renewed for purposes of Section 424(h) of the Code). Notwithstanding the foregoing, in the case of an Option or Stock Appreciation Right that is a Substitute Award, the exercise price per share of the Shares subject to such Option or Stock Appreciation Right, as applicable, may be less than the Fair Market Value per share on the date of grant; provided that the exercise price of any Substitute Award shall be determined in accordance with the applicable requirements of Section 424 and 409A of the Code.  

6.4Option and SAR Term. The term of each Option (the “Option Term”) and the term of each Stock Appreciation Right (the “SAR Term”) shall be set by the Administrator in its sole discretion; provided, however, that the Option Term or SAR Term, as applicable, shall not be more than (a) ten (10) years from the date the Option or Stock Appreciation Right, as applicable, is granted to an Eligible Individual (other than a Greater Than 10% Stockholder), or (b) five (5) years from the date an Incentive Stock Option is granted to a Greater Than 10% Stockholder. Except as limited by the requirements of Section 409A or Section 422 of the Code and regulations and rulings thereunder or the first sentence of this Section 6.4 and without limiting the Company’s rights under Section 11.7, the Administrator may extend the Option Term of any outstanding Option or the SAR Term of any outstanding Stock Appreciation Right, and may extend the time period during which vested Options or Stock Appreciation Rights may be exercised, in connection with any Termination of Service of the Holder or otherwise, and may amend, subject to Section 11.7 and 13.1, any other term or condition of such Option or Stock Appreciation Right relating to such Termination of Service of the Holder or otherwise.

6.5Option and SAR Vesting.  The period during which the right to exercise, in whole or in part, an Option or Stock Appreciation Right vests in the Holder shall be set by the Administrator and set forth in the applicable Award Agreement. Unless otherwise determined by the Administrator in the Award Agreement, the applicable Program or by action of the Administrator following the grant of the Option or Stock Appreciation Right, (a) no portion of an Option or Stock Appreciation Right which is unexercisable at a Holder’s Termination of Service shall thereafter become exercisable and (b) the portion of an Option or Stock Appreciation Right that is unexercisable at a Holder’s Termination of Service shall automatically expire on the date of such Termination of Service.

 


 

ARTICLE 7.

EXERCISE OF OPTIONS
and STOCK APPRECIATION RIGHTS

7.1Exercise and Payment. An exercisable Option or Stock Appreciation Right may be exercised in whole or in part. However, an Option or Stock Appreciation Right shall not be exercisable with respect to fractional Shares and the Administrator may require that, by the terms of the Option or Stock Appreciation Right, a partial exercise must be with respect to a minimum number of Shares. Payment of the amounts payable with respect to Stock Appreciation Rights pursuant to this Article 7 shall be in cash, Shares (based on its Fair Market Value as of the date the Stock Appreciation Right is exercised), or a combination of both, as determined by the Administrator.

7.2Manner of Exercise. Except as set forth in Section 7.3, all or a portion of an exercisable Option or Stock Appreciation Right shall be deemed exercised upon delivery of all of the following to the Secretary of the Company, the stock plan administrator of the Company or such other person or entity designated by the Administrator, or his, her or its office, as applicable:

(a)A written or electronic notice complying with the applicable rules established by the Administrator stating that the Option or Stock Appreciation Right, or a portion thereof, is exercised. The notice shall be signed or otherwise acknowledge electronically by the Holder or other person then entitled to exercise the Option or Stock Appreciation Right or such portion thereof;

(b)Such representations and documents as the Administrator, in its sole discretion, deems necessary or advisable to effect compliance with Applicable Law.

(c)In the event that the Option shall be exercised pursuant to Section 11.3 by any person or persons other than the Holder, appropriate proof of the right of such person or persons to exercise the Option or Stock Appreciation Right, as determined in the sole discretion of the Administrator; and

(d)Full payment of the exercise price and applicable withholding taxes for the Shares with respect to which the Option or Stock Appreciation Right, or portion thereof, is exercised, in a manner permitted by the Administrator in accordance with Sections 11.1 and 11.2.

7.3Notification Regarding Disposition. The Holder shall give the Company or its designee prompt written or electronic notice of any disposition of Shares acquired by exercise of an Incentive Stock Option which occurs within (a) two years from the date of granting (including the date the Option is modified, extended or renewed for purposes of Section 424(h) of the Code) such Option to such Holder, or (b) one year after the date of transfer of such Shares to such Holder. Such notice shall specify the date of such disposition or other transfer and the amount realized, in cash, other property, assumption of indebtedness or other consideration, by the Holder in such disposition or other transfer.

 


 

ARTICLE 8.

AWARD OF RESTRICTED STOCK

8.1Award of Restricted Stock. The Administrator is authorized to grant Restricted Stock to Eligible Individuals, and shall determine the terms and conditions, including the restrictions applicable to each award of Restricted Stock, which terms and conditions shall not be inconsistent with the Plan or any applicable Program, and may impose such conditions on the issuance of such Restricted Stock as it deems appropriate. The Administrator shall establish the purchase price, if any, and form of payment for Restricted Stock; provided, however, that if a purchase price is charged, such purchase price shall be no less than the par value, if any, of the Shares to be purchased, unless otherwise permitted by Applicable Law. In all cases, legal consideration shall be required for each issuance of Restricted Stock to the extent required by Applicable Law.

8.2Rights as Stockholders. Subject to Section 8.4, upon issuance of Restricted Stock, the Holder shall have, unless otherwise provided by the Administrator, all the rights of a stockholder with respect to said Shares, subject to the restrictions in the Plan, any applicable Program and/or the applicable Award Agreement, including the right to receive all dividends and other distributions paid or made with respect to the Shares to the extent such dividends and other distributions have a record date that is on or after the date on which the Holder to whom such Restricted Stock are granted becomes the record holder of such Restricted Stock; provided, however, that, in the sole discretion of the Administrator, any extraordinary distributions with respect to the Shares may be subject to the restrictions set forth in Section 8.3. In addition, with respect to a share of Restricted Stock with performance-based vesting, dividends which are paid prior to vesting shall only be paid out to the Holder to the extent that the performance-based vesting conditions are subsequently satisfied and the share of Restricted Stock vests.

8.3Restrictions. All shares of Restricted Stock (including any shares received by Holders thereof with respect to shares of Restricted Stock as a result of stock dividends, stock splits or any other form of recapitalization) shall be subject to such restrictions and vesting requirements as the Administrator shall provide in the applicable Program or Award Agreement. By action taken after the Restricted Stock is issued, the Administrator may, upon a Change in Control, or the Holder’s death or disability, accelerate the vesting of such Restricted Stock by removing any or all of the restrictions imposed by the terms of the applicable Program or Award Agreement.

8.4Repurchase or Forfeiture of Restricted Stock. If no price was paid by the Holder for the Restricted Stock, upon a Termination of Service during the applicable restriction period, the Holder’s rights in unvested Restricted Stock then subject to restrictions shall lapse, and such Restricted Stock shall be surrendered to the Company and cancelled without consideration on the date of such Termination of Service. If a price was paid by the Holder for the Restricted Stock, upon a Termination of Service during the applicable restriction period, the Company shall have the right to repurchase from the Holder the unvested Restricted Stock then subject to restrictions at a cash price per share equal to the price paid by the Holder for such Restricted Stock or such other amount as may be specified in the applicable Program or Award Agreement. Notwithstanding the foregoing, the Administrator, in its sole discretion, may provide that upon a

 


 

Change in Control, or the Holder’s death or disability, the Holder’s rights in unvested Restricted Stock then subject to restrictions shall not lapse, such Restricted Stock shall vest and cease to be forfeitable and, if applicable, the Company shall cease to have a right of repurchase.

8.5Section 83(b) Election. If a Holder makes an election under Section 83(b) of the Code to be taxed with respect to the Restricted Stock as of the date of transfer of the Restricted Stock rather than as of the date or dates upon which the Holder would otherwise be taxable under Section 83(a) of the Code, the Holder shall be required to deliver a copy of such election to the Company promptly after filing such election with the Internal Revenue Service along with proof of the timely filing thereof with the Internal Revenue Service.

ARTICLE 9.

Award of restricted stock units

9.1Grant of Restricted Stock Units. The Administrator is authorized to grant Awards of Restricted Stock Units to any Eligible Individual selected by the Administrator in such amounts and subject to such terms and conditions as determined by the Administrator.

9.2Term. Except as otherwise provided herein, the term of a Restricted Stock Unit award shall be set by the Administrator in its sole discretion.

9.3Purchase Price. The Administrator shall specify the purchase price, if any, to be paid by the Holder to the Company with respect to any Restricted Stock Unit award; provided, however, that value of the consideration shall not be less than the par value of a Share, unless otherwise permitted by Applicable Law.

9.4Vesting of Restricted Stock Units. At the time of grant, the Administrator shall specify the date or dates on which the Restricted Stock Units shall become fully vested and nonforfeitable, and may specify such conditions to vesting as it deems appropriate, including, without limitation, vesting based upon the Holder’s duration of service to the Company or any Subsidiary, one or more Performance Criteria, Company performance, individual performance or other specific criteria, in each case on a specified date or dates or over any period or periods, as determined by the Administrator.

9.5Maturity and Payment. At the time of grant, the Administrator shall specify the maturity date applicable to each grant of Restricted Stock Units, which shall be no earlier than the vesting date or dates of the Award and may be determined at the election of the Holder (if permitted by the applicable Award Agreement); provided that, except as otherwise determined by the Administrator, and subject to compliance with Section 409A, in no event shall the maturity date relating to each Restricted Stock Unit occur following the later of (a) the 15th day of the third month following the end of calendar year in which the applicable portion of the Restricted Stock Unit vests; or (b) the 15th day of the third month following the end of the Company’s fiscal year in which the applicable portion of the Restricted Stock Unit vests. On the maturity date, the Company shall, in accordance with the applicable Award Agreement and subject to Section 11.4(f), transfer to the Holder one unrestricted, fully transferable Share for each Restricted Stock Unit scheduled to be paid out on such date and not previously forfeited, or in the sole discretion of

 


 

the Administrator, an amount in cash equal to the Fair Market Value of such Shares on the maturity date or a combination of cash and Common Stock as determined by the Administrator.

9.6Payment upon Termination of Service. An Award of Restricted Stock Units shall only be payable while the Holder is an Employee, a Consultant or a member of the Board, as applicable; provided, however, that the Administrator, in its sole discretion, may provide (in an Award Agreement or otherwise) that a Restricted Stock Unit award may be paid subsequent to a Termination of Service in certain events, including a Change in Control, the Holder’s death, retirement or disability or any other specified Termination of Service.

ARTICLE 10.

award of OTHER STOCK OR CASH BASED AWARDS and DIVIDEND EQUIVALENTS

10.1Other Stock or Cash Based Awards.  The Administrator is authorized to (a) grant Other Stock or Cash Based Awards, including awards entitling a Holder to receive Shares or cash to be delivered immediately or in the future, to any Eligible Individual and (b) determine whether such Other Stock or Cash Based Awards shall be Performance-Based Compensation. Subject to the provisions of the Plan and any applicable Program, the Administrator shall determine the terms and conditions of each Other Stock or Cash Based Award, including the term of the Award, any exercise or purchase price, performance goals, including the Performance Criteria, transfer restrictions, vesting conditions and other terms and conditions applicable thereto, which shall be set forth in the applicable Award Agreement. Other Stock or Cash Based Awards may be paid in cash, Shares, or a combination of cash and Shares, as determined by the Administrator, and may be available as a form of payment in the settlement of other Awards granted under the Plan, as stand-alone payments, as a part of a bonus, deferred bonus, deferred compensation or other arrangement, and/or as payment in lieu of compensation to which an Eligible Individual is otherwise entitled.

10.2Dividend Equivalents. Dividend Equivalents may be granted by the Administrator, either alone or in tandem with another Award, based on dividends declared on the Common Stock, to be credited as of dividend payment dates during the period between the date the Dividend Equivalents are granted to a Holder and the date such Dividend Equivalents terminate or expire, as determined by the Administrator. Such Dividend Equivalents shall be converted to cash or additional Shares by such formula and at such time and subject to such restrictions and limitations as may be determined by the Administrator. In addition, Dividend Equivalents with respect to an Award with performance-based vesting that are based on dividends paid prior to the vesting of such Award shall only be paid out to the Holder to the extent that the performance-based vesting conditions are subsequently satisfied and the Award vests. Notwithstanding the foregoing, no Dividend Equivalents shall be payable with respect to Options or Stock Appreciation Rights.

ARTICLE 11.

ADditional terms of awards

11.1Payment. The Administrator shall determine the method or methods by which payments by any Holder with respect to any Awards granted under the Plan shall be made,

 


 

including, without limitation: (a) cash or check, (b) Shares (including Shares issuable pursuant to the exercise, vesting or payment of the Award) or Shares held for such minimum period of time as may be established by the Administrator, in each case, having a Fair Market Value on the date of delivery equal to the aggregate payments required, (c) delivery of a written or electronic notice that the Holder has placed a market sell order with a broker acceptable to the Company with respect to Shares then issuable upon exercise or vesting of an Award, and that the broker has been directed to pay a sufficient portion of the net proceeds of the sale to the Company in satisfaction of the aggregate payments required; provided that payment of such proceeds is then made to the Company upon settlement of such sale, (d) other form of legal consideration acceptable to the Administrator in its sole discretion, or (e) any combination of the above permitted forms of payment. Notwithstanding any other provision of the Plan to the contrary, no Holder who is a Director or an executive officer of the Company within the meaning of Section 13(k) of the Exchange Act shall be permitted to make payment with respect to any Awards granted under the Plan, or continue any extension of credit with respect to such payment, with a loan from the Company or a loan arranged by the Company in violation of Section 13(k) of the Exchange Act.

11.2Tax Withholding. The Company or any Subsidiary shall have the authority and the right to deduct or withhold, or require a Holder to remit to the Company, an amount sufficient to satisfy federal, state, local and foreign taxes (including the Holder’s FICA, employment tax or other social security contribution obligation) required by law to be withheld with respect to any taxable event concerning a Holder arising as a result of the Plan or any Award. The Administrator may, in its sole discretion and in satisfaction of the foregoing requirement, allow a Holder to satisfy such obligations by any payment means described in Section 11.1 hereof, including without limitation, by allowing such Holder to have the Company or any Subsidiary withhold Shares otherwise issuable under an Award (or allow the surrender of Shares). The number of Shares which may be so withheld or surrendered shall be limited to the number of Shares which have a fair market value on the date of withholding or repurchase no greater than the aggregate amount of such liabilities based on the minimum statutory withholding rates for federal, state, local and foreign income tax and payroll tax purposes that are applicable to such supplemental taxable income (or such other number as would not result in adverse financial accounting consequences for the Company or any of its Subsidiaries). The Administrator shall determine the fair market value of the Shares, consistent with applicable provisions of the Code, for tax withholding obligations due in connection with a broker-assisted cashless Option or Stock Appreciation Right exercise involving the sale of Shares to pay the Option or Stock Appreciation Right exercise price or any tax withholding obligation.

11.3Transferability of Awards.

(a)Except as otherwise provided in Sections 11.3(b) and 11.3(c):

(i)No Award under the Plan may be sold, pledged, assigned or transferred in any manner other than (A) by will or the laws of descent and distribution or (B) subject to the consent of the Administrator, pursuant to a DRO, unless and until such Award has been exercised or the Shares underlying such Award have been issued, and all restrictions applicable to such Shares have lapsed;

 


 

(ii)No Award or interest or right therein shall be liable for or otherwise subject to the debts, contracts or engagements of the Holder or the Holder’s successors in interest or shall be subject to disposition by transfer, alienation, anticipation, pledge, hypothecation, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy) unless and until such Award has been exercised, or the Shares underlying such Award have been issued, and all restrictions applicable to such Shares have lapsed, and any attempted disposition of an Award prior to satisfaction of these conditions shall be null and void and of no effect, except to the extent that such disposition is permitted by Section 11.3(a)(i); and

(iii)During the lifetime of the Holder, only the Holder may exercise any exercisable portion of an Award granted to such Holder under the Plan, unless it has been disposed of pursuant to a DRO.  After the death of the Holder, any exercisable portion of an Award may, prior to the time when such portion becomes unexercisable under the Plan or the applicable Program or Award Agreement, be exercised by the Holder’s personal representative or by any person empowered to do so under the deceased Holder’s will or under the then-applicable laws of descent and distribution.

(b)Notwithstanding Section 11.3(a), the Administrator, in its sole discretion, may determine to permit a Holder or a Permitted Transferee of such Holder to transfer an Award other than an Incentive Stock Option (unless such Incentive Stock Option is intended to become a Nonqualified Stock Option) to any one or more Permitted Transferees of such Holder, subject to the following terms and conditions: (i) an Award transferred to a Permitted Transferee shall not be assignable or transferable by the Permitted Transferee other than (A) to another Permitted Transferee of the applicable Holder or (B) by will or the laws of descent and distribution or, subject to the consent of the Administrator, pursuant to a DRO; (ii) an Award transferred to a Permitted Transferee shall continue to be subject to all the terms and conditions of the Award as applicable to the original Holder (other than the ability to further transfer the Award to any Person other than another Permitted Transferee of the applicable Holder); and (iii) the Holder (or transferring Permitted Transferee) and the receiving Permitted Transferee shall execute any and all documents requested by the Administrator, including, without limitation documents to (A) confirm the status of the transferee as a Permitted Transferee, (B) satisfy any requirements for an exemption for the transfer under Applicable Law and (C) evidence the transfer.  In addition, and further notwithstanding Section 11.3(a), hereof, the Administrator, in its sole discretion, may determine to permit a Holder to transfer Incentive Stock Options to a trust that constitutes a Permitted Transferee if, under Section 671 of the Code and other Applicable Law, the Holder is considered the sole beneficial owner of the Incentive Stock Option while it is held in the trust.  

(c)Notwithstanding Section 11.3(a), a Holder may, in the manner determined by the Administrator, designate a beneficiary to exercise the rights of the Holder and to receive any distribution with respect to any Award upon the Holder’s death. A beneficiary, legal guardian, legal representative, or other person claiming any rights pursuant to the Plan is subject to all terms and conditions of the Plan and any Program or Award Agreement applicable to the Holder and any additional restrictions deemed necessary or appropriate by the Administrator. If the Holder is married or a domestic partner in a domestic partnership qualified under Applicable Law and resides in a community property state, a designation of a person other than the Holder’s spouse or domestic

 


 

partner, as applicable, as the Holder’s beneficiary with respect to more than 50% of the Holder’s interest in the Award shall not be effective without the prior written or electronic consent of the Holder’s spouse or domestic partner. If no beneficiary has been designated or survives the Holder, payment shall be made to the person entitled thereto pursuant to the Holder’s will or the laws of descent and distribution. Subject to the foregoing, a beneficiary designation may be changed or revoked by a Holder at any time; provided that the change or revocation is delivered in writing to the Administrator prior to the Holder’s death.

11.4Conditions to Issuance of Shares.

(a)The Administrator shall determine the methods by which Shares shall be delivered or deemed to be delivered to Holders. Notwithstanding anything herein to the contrary, the Company shall not be required to issue or deliver any certificates or make any book entries evidencing Shares pursuant to the exercise of any Award, unless and until the Administrator has determined, with advice of counsel, that the issuance of such Shares is in compliance with Applicable Law and the Shares are covered by an effective registration statement or applicable exemption from registration. In addition to the terms and conditions provided herein, the Administrator may require that a Holder make such reasonable covenants, agreements and representations as the Administrator, in its sole discretion, deems advisable in order to comply with Applicable Law.

(b)All share certificates delivered pursuant to the Plan and all Shares issued pursuant to book entry procedures are subject to any stop-transfer orders and other restrictions as the Administrator deems necessary or advisable to comply with Applicable Law. The Administrator may place legends on any share certificate or book entry to reference restrictions applicable to the Shares (including, without limitation, restrictions applicable to Restricted Stock).

(c)The Administrator shall have the right to require any Holder to comply with any timing or other restrictions with respect to the settlement, distribution or exercise of any Award, including a window-period limitation, as may be imposed in the sole discretion of the Administrator.

(d)No fractional Shares shall be issued and the Administrator, in its sole discretion, shall determine whether cash shall be given in lieu of fractional Shares or whether such fractional Shares shall be eliminated by rounding down.

(e)The Company, in its sole discretion, may (i) retain physical possession of any stock certificate evidencing Shares until any restrictions thereon shall have lapsed and/or (ii) require that the stock certificates evidencing such Shares be held in custody by a designated escrow agent (which may but need not be the Company) until the restrictions thereon shall have lapsed, and that the Holder deliver a stock power, endorsed in blank, relating to such Shares.

11.5Forfeiture and Claw-Back Provisions. All Awards (including any proceeds, gains or other economic benefit actually or constructively received by a Holder upon any receipt or exercise of any Award or upon the receipt or resale of any Shares underlying the Award and any payments of a portion of an incentive-based bonus pool allocated to a Holder) shall be subject to the provisions of any claw-back policy implemented by the Company, including, without

 


 

limitation, any claw-back policy adopted to comply with the requirements of Applicable Law, including, without limitation, the Dodd-Frank Wall Street Reform and Consumer Protection Act and any rules or regulations promulgated thereunder, whether or not such claw-back policy was in place at the time of grant of an Award, to the extent set forth in such claw-back policy and/or in the applicable Award Agreement.

11.6Prohibition on Repricing. Subject to Section 13.2, the Administrator shall not, without the approval of the stockholders of the Company, (a) authorize the amendment of any outstanding Option or Stock Appreciation Right to reduce its price per Share, or (b) cancel any Option or Stock Appreciation Right in exchange for cash or another Award when the Option or Stock Appreciation Right price per Share exceeds the Fair Market Value of the underlying Shares. Furthermore, for purposes of this Section 11.6, except in connection with a corporate transaction involving the Company (including, without limitation, any stock dividend, stock split, extraordinary cash dividend, recapitalization, reorganization, merger, consolidation, split-up, spin-off, combination or exchange of shares), the terms of outstanding Awards may not be amended to reduce the exercise price per Share of outstanding Options or Stock Appreciation Rights or cancel outstanding Options or Stock Appreciation Rights in exchange for cash, other Awards or Options or Stock Appreciation Rights with an exercise price per Share that is less than the exercise price per Share of the original Options or Stock Appreciation Rights without the approval of the stockholders of the Company.

11.7Amendment of Awards.  Subject to Applicable Law, the Administrator may amend, modify or terminate any outstanding Award, including but not limited to, substituting therefor another Award of the same or a different type, changing the date of exercise or settlement, and converting an Incentive Stock Option to a Non-Qualified Stock Option.  The Holder’s consent to such action shall be required unless (a) the Administrator determines that the action, taking into account any related action, would not materially and adversely affect the Holder, or (b) the change is otherwise permitted under the Plan (including, without limitation, under Section 13.2 or 13.10).

11.8Data Privacy.  As a condition of receipt of any Award, each Holder explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of personal data as described in this Section 11.8 by and among, as applicable, the Company and its Subsidiaries for the exclusive purpose of implementing, administering and managing the Holder’s participation in the Plan.  The Company and its Subsidiaries may hold certain personal information about a Holder, including but not limited to, the Holder’s name, home address and telephone number, date of birth, social security or insurance number or other identification number, salary, nationality, job title(s), any shares of stock held in the Company or any of its Subsidiaries, details of all Awards, in each case, for the purpose of implementing, managing and administering the Plan and Awards (the “Data”).  The Company and its Subsidiaries may transfer the Data amongst themselves as necessary for the purpose of implementation, administration and management of a Holder’s participation in the Plan, and the Company and its Subsidiaries may each further transfer the Data to any third parties assisting the Company and its Subsidiaries in the implementation, administration and management of the Plan.  These recipients may be located in the Holder’s country, or elsewhere, and the Holder’s country may have different data privacy laws and protections than the recipients’ country.  Through acceptance of an Award, each Holder authorizes such recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing the Holder’s participation in the

 


 

Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom the Company or any of its  Subsidiaries or the Holder may elect to deposit any Shares.  The Data related to a Holder will be held only as long as is necessary to implement, administer, and manage the Holder’s participation in the Plan.  A Holder may, at any mutually agreed time, view the Data held by the Company with respect to such Holder, request additional information about the storage and processing of the Data with respect to such Holder, recommend any necessary corrections to the Data with respect to the Holder or refuse or withdraw the consents herein in writing, in any case without cost, by contacting his or her local human resources representative.  The Company may cancel Holder’s ability to participate in the Plan and, in the Administrator’s discretion, the Holder may forfeit any outstanding Awards if the Holder refuses or withdraws his or her consents as described herein.  For more information on the consequences of refusal to consent or withdrawal of consent, Holders may contact their local human resources representative.

ARTICLE 12.

ADMINISTRATION

12.1Administrator. The Committee shall administer the Plan (except as otherwise permitted herein). To the extent necessary to comply with Rule 16b-3 of the Exchange Act, and with respect to Awards that are intended to be Performance-Based Compensation, including Options and Stock Appreciation Rights, then the Committee shall take all action with respect to such Awards, and the individuals taking such action shall consist solely of two or more Non-Employee Directors, each of whom is intended to qualify as both a “non-employee director” as defined by Rule 16b-3 of the Exchange Act or any successor rule and an “outside director” for purposes of Section 162(m) of the Code. Additionally, to the extent required by Applicable Law, each of the individuals constituting the Committee shall be an “independent director” under the rules of any securities exchange or automated quotation system on which the Shares are listed, quoted or traded. Notwithstanding the foregoing, any action taken by the Committee shall be valid and effective, whether or not members of the Committee at the time of such action are later determined not to have satisfied the requirements for membership set forth in this Section 12.1 or the Organizational Documents.  Except as may otherwise be provided in the Organizational Documents or as otherwise required by Applicable Law, (a) Committee members may resign at any time by delivering written or electronic notice to the Board and (b) vacancies in the Committee may only be filled by the Board.  Notwithstanding the foregoing, (i) the full Board, acting by a majority of its members in office, shall conduct the general administration of the Plan with respect to Awards granted to Non-Employee Directors and, with respect to such Awards, the terms “Administrator” as used in the Plan shall be deemed to refer to the Board and (ii) the Board or Committee may delegate its authority hereunder to the extent permitted by Section 12.7.

12.2Duties and Powers of Administrator. It shall be the duty of the Administrator to conduct the general administration of the Plan in accordance with its provisions. The Administrator shall have the power to interpret the Plan, all Programs and Award Agreements, and to adopt such rules for the administration, interpretation and application of the Plan and any Program as are not inconsistent with the Plan, to interpret, amend or revoke any such rules and to amend the Plan or any Program or Award Agreement; provided that the rights or obligations of the Holder of the

 


 

Award that is the subject of any such Program or Award Agreement are not materially and adversely affected by such amendment, unless the consent of the Holder is obtained or such amendment is otherwise permitted under Section 11.5 or Section 13.10. In its sole discretion, the Board may at any time and from time to time exercise any and all rights and duties of the Committee in its capacity as the Administrator under the Plan except with respect to matters which under Rule 16b‑3 under the Exchange Act or any successor rule, or Section 162(m) of the Code, or any regulations or rules issued thereunder, or the rules of any securities exchange or automated quotation system on which the Shares are listed, quoted or traded are required to be determined in the sole discretion of the Committee.

12.3Action by the Administrator. Unless otherwise established by the Board, set forth in any Organizational Documents or as required by Applicable Law, a majority of the Administrator shall constitute a quorum and the acts of a majority of the members present at any meeting at which a quorum is present, and acts approved in writing by all members of the Administrator in lieu of a meeting, shall be deemed the acts of the Administrator. Each member of the Administrator is entitled to, in good faith, rely or act upon any report or other information furnished to that member by any officer or other employee of the Company or any Subsidiary, the Company’s independent certified public accountants, or any executive compensation consultant or other professional retained by the Company to assist in the administration of the Plan.

12.4Authority of Administrator. Subject to the Organizational Documents, any specific designation in the Plan and Applicable Law, the Administrator has the exclusive power, authority and sole discretion to:

(a)Designate Eligible Individuals to receive Awards;

(b)Determine the type or types of Awards to be granted to each Eligible Individual (including, without limitation, any Awards granted in tandem with another Award granted pursuant to the Plan);

(c)Determine the number of Awards to be granted and the number of Shares to which an Award will relate;

(d)Determine the terms and conditions of any Award granted pursuant to the Plan, including, but not limited to, the exercise price, grant price, purchase price, any Performance Criteria or performance criteria, any restrictions or limitations on the Award, any schedule for vesting, lapse of forfeiture restrictions or restrictions on the exercisability of an Award, and accelerations or waivers thereof, subject to Section 12.5, and any provisions related to non-competition and claw-back and recapture of gain on an Award, based in each case on such considerations as the Administrator in its sole discretion determines;

(e)Determine whether, to what extent, and under what circumstances an Award may be settled in, or the exercise price of an Award may be paid in cash, Shares, other Awards, or other property, or an Award may be canceled, forfeited, or surrendered;

(f)Prescribe the form of each Award Agreement, which need not be identical for each Holder;

 


 

(g)Decide all other matters that must be determined in connection with an Award;

(h)Establish, adopt, or revise any Programs, rules and regulations as it may deem necessary or advisable to administer the Plan;

(i)Interpret the terms of, and any matter arising pursuant to, the Plan, any Program or any Award Agreement;

(j)Make all other decisions and determinations that may be required pursuant to the Plan or as the Administrator deems necessary or advisable to administer the Plan; and

(k)Accelerate wholly or partially the vesting or lapse of restrictions of any Award or portion thereof at any time after the grant of an Award, subject to whatever terms and conditions it selects and Section 12.5 and Section 13.2.

12.5No Discretionary Acceleration of Vesting.  Notwithstanding any provision of the Plan to the contrary, the Administrator shall not exercise discretion to provide for accelerated vesting, exercisability or distribution of any Award granted under the Plan except in the event of (i) the Participant’s death, disability, (ii) upon or following a Change in Control, or (iii) if the Participant is a non-employee director, the Participant’s Termination of Service for any reason after serving a minimum of at least one-half of the relevant term under any Award Agreement.  

12.6Decisions Binding. The Administrator’s interpretation of the Plan, any Awards granted pursuant to the Plan, any Program or any Award Agreement and all decisions and determinations by the Administrator with respect to the Plan are final, binding and conclusive on all Persons.

12.7Delegation of Authority. The Board or Committee may from time to time delegate to a committee of one or more members of the Board or one or more officers of the Company the authority to grant or amend Awards or to take other administrative actions pursuant to this Article 12; provided, however, that in no event shall an officer of the Company be delegated the authority to grant Awards to, or amend Awards held by, the following individuals: (a) individuals who are subject to Section 16 of the Exchange Act, (b) Covered Employees with respect to Awards intended to constitute Performance Based Compensation, or (c) officers of the Company (or Directors) to whom authority to grant or amend Awards has been delegated hereunder; provided, further, that any delegation of administrative authority shall only be permitted to the extent it is permissible under any Organizational Documents and Applicable Law (including, without limitation, Section 162(m) of the Code). Any delegation hereunder shall be subject to the restrictions and limits that the Board or Committee specifies at the time of such delegation or that are otherwise included in the applicable Organizational Documents, and the Board or Committee, as applicable, may at any time rescind the authority so delegated or appoint a new delegatee. At all times, the delegatee appointed under this Section 12.7 shall serve in such capacity at the pleasure of the Board or the Committee, as applicable, and the Board or the Committee may abolish any committee at any time and re-vest in itself any previously delegated authority.

 


 

ARTICLE 13.

MISCELLANEOUS PROVISIONS

13.1Amendment, Suspension or Termination of the Plan.

(a)Except as otherwise provided in Section 13.1(b), the Plan may be wholly or partially amended or otherwise modified, suspended or terminated at any time or from time to time by the Board; provided that, except as provided in Section 11.5 and Section 13.10, no amendment, suspension or termination of the Plan shall, without the consent of the Holder, materially and adversely affect any rights or obligations under any Award theretofore granted or awarded, unless the Award itself otherwise expressly so provides.

(b)Notwithstanding Section 13.1(a), the Board may not, except as provided in Section 13.2, take any of the following actions without approval of the Company’s stockholders given within twelve (12) months before or after such action: (i) increase the limit imposed in Section 3.1 on the maximum number of Shares which may be issued under the Plan or the Award Limit, (ii) reduce the price per share of any outstanding Option or Stock Appreciation Right granted under the Plan or take any action prohibited under Section 11.6, or (iii) cancel any Option or Stock Appreciation Right in exchange for cash or another Award in violation of Section 11.6.

(c)No Awards may be granted or awarded during any period of suspension or after termination of the Plan, and notwithstanding anything herein to the contrary, in no event may any Award be granted under the Plan after the tenth (10th) anniversary of the earlier of (i) the date on which the Plan was adopted by the Board or (ii) the date the Plan was approved by the Company’s stockholders (such anniversary, the “Expiration Date”). Any Awards that are outstanding on the Expiration Date shall remain in force according to the terms of the Plan, the applicable Program and the applicable Award Agreement.

13.2Changes in Common Stock or Assets of the Company, Acquisition or Liquidation of the Company and Other Corporate Events.

(a)In the event of any stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of the Company’s stock or the share price of the Company’s stock other than an Equity Restructuring, the Administrator may make equitable adjustments, if any, to reflect such change with respect to: (i) the aggregate number and kind of Shares that may be issued under the Plan (including, but not limited to, adjustments of the limitations in Section 3.1 on the maximum number and kind of Shares which may be issued under the Plan, and adjustments of the Award Limit); (ii) the number and kind of Shares (or other securities or property) subject to outstanding Awards; (iii) the terms and conditions of any outstanding Awards (including, without limitation, any applicable performance targets or criteria with respect thereto); and (iv) the grant or exercise price per share for any outstanding Awards under the Plan. Any adjustment affecting an Award intended as Performance-Based Compensation shall be made consistent with the requirements of Section 162(m) of the Code unless otherwise determined by the Administrator.

 


 

(b)In the event of any transaction or event described in Section 13.2(a) or any unusual or nonrecurring transactions or events affecting the Company, any Subsidiary of the Company, or the financial statements of the Company or any Subsidiary, or of changes in Applicable Law or Applicable Accounting Standards, the Administrator, in its sole discretion, and on such terms and conditions as it deems appropriate, either by the terms of the Award or by action taken prior to the occurrence of such transaction or event, is hereby authorized to take any one or more of the following actions whenever the Administrator determines that such action is appropriate in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan or with respect to any Award under the Plan, to facilitate such transactions or events or to give effect to such changes in Applicable Law or Applicable Accounting Standards:

(i)To provide for the termination of any such Award in exchange for an amount of cash and/or other property with a value equal to the amount that would have been attained upon the exercise of such Award or realization of the Holder’s rights (and, for the avoidance of doubt, if as of the date of the occurrence of the transaction or event described in this Section 13.2 the Administrator determines in good faith that no amount would have been attained upon the exercise of such Award or realization of the Holder’s rights, then such Award may be terminated by the Company without payment);

(ii)To provide that such Award be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted for by similar options, rights or awards covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the number and kind of shares and applicable exercise or purchase price, in all cases, as determined by the Administrator;

(iii)To make adjustments in the number and type of Shares of the Company’s stock (or other securities or property) subject to outstanding Awards, and/or in the terms and conditions of (including the grant or exercise price), and the criteria included in, outstanding Awards and Awards which may be granted in the future;

(iv)To provide that such Award shall be exercisable or payable or fully vested with respect to all Shares covered thereby, notwithstanding anything to the contrary in the Plan or the applicable Program or Award Agreement;

(v)To replace such Award with other rights or property selected by the Administrator; and/or

(vi)To provide that the Award cannot vest, be exercised or become payable after such event.

(c)In connection with the occurrence of any Equity Restructuring, and notwithstanding anything to the contrary in Sections 13.2(a) and 13.2(b):

(i)The number and type of securities subject to each outstanding Award and the exercise price or grant price thereof, if applicable, shall be equitably adjusted (and the adjustments provided under this Section 13.2(c)(i) shall be nondiscretionary and shall be final and binding on the affected Holder and the Company); and/or

 


 

(ii)The Administrator shall make such equitable adjustments, if any, as the Administrator, in its sole discretion, may deem appropriate to reflect such Equity Restructuring with respect to the aggregate number and kind of Shares that may be issued under the Plan (including, but not limited to, adjustments of the limitation in Section 3.1 on the maximum number and kind of Shares which may be issued under the Plan, and adjustments of the Award Limit).

(d)Notwithstanding any other provision of the Plan, in the event of a Change in Control, each outstanding Award shall be assumed or an equivalent Award substituted by the successor corporation or a parent or subsidiary of the successor corporation, in each case, as determined by the Administrator.

(e)In the event that the successor corporation in a Change in Control and its parents and subsidiaries refuse to assume or substitute for any Award in accordance with Section 13.2(d) hereof, each such non-assumed/substituted Award, except for any Performance Awards, shall become fully vested and, as applicable, exercisable and shall be deemed exercised, immediately prior to the consummation of such transaction, and all forfeiture restrictions on any or all such Awards shall lapse at such time. For the avoidance of doubt, the vesting of any Performance Awards not assumed in a Change in Control will not be automatically accelerated pursuant to this Section 13.2(e) and will instead vest pursuant to the terms and conditions of the applicable Award Agreement upon a Change in Control where the successor corporation and its parents and subsidiaries refuse to assume or substitute for any Award in accordance with Section 13.2(d) hereof.   For the avoidance of doubt, if the value of an Award that is terminated in connection with this Section 13.2(e) is zero or negative at the time of such Change in Control, such Award shall be terminated upon the Change in Control without payment of consideration therefor.  Notwithstanding anything to the contrary, in the event that, within the twelve (12) month period immediately following a Change in Control, a Holder experiences a Termination of Service by the Company for other than Cause or by a Holder for Good Reason, then the vesting and, if applicable, exercisability of that number of Shares equal to one hundred percent (100%) of the then-unvested Shares subject to the outstanding assumed Awards held by such Holder shall accelerate upon the date of such Termination of Service.

(f)For the purposes of this Section 13.2, an Award shall be considered assumed if, following the Change in Control, the Award confers the right to purchase or receive, for each Share subject to the Award immediately prior to the Change in Control, the consideration (whether stock, cash, or other securities or property) received in the Change in Control by holders of Common Stock for each Share held on the effective date of the transaction (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding Shares); provided, however, that if such consideration received in the Change in Control was not solely common stock of the successor corporation or its parent, the Administrator may, with the consent of the successor corporation, provide for the consideration to be received upon the exercise of the Award, for each Share subject to an Award, to be solely common stock of the successor corporation or its parent equal in fair market value to the per-share consideration received by holders of Common Stock in the Change in Control.

(g)The Administrator, in its sole discretion, may include such further provisions and limitations in any Award, agreement or certificate, as it may deem equitable and in the best interests of the Company that are not inconsistent with the provisions of the Plan.

 


 

(h)Unless otherwise determined by the Administrator, no adjustment or action described in this Section 13.2 or in any other provision of the Plan shall be authorized to the extent it would (i) with respect to Awards which are granted to Covered Employees and are intended to qualify as Performance-Based Compensation, cause such Award to fail to so qualify as Performance-Based Compensation, (ii) cause the Plan to violate Section 422(b)(1) of the Code, (iii) result in short-swing profits liability under Section 16 of the Exchange Act or violate the exemptive conditions of Rule 16b-3 of the Exchange Act, or (iv) cause an Award to fail to be exempt from or comply with Section 409A.

(i)The existence of the Plan, any Program, any Award Agreement and/or the Awards granted hereunder shall not affect or restrict in any way the right or power of the Company or the stockholders of the Company to make or authorize any adjustment, recapitalization, reorganization or other change in the Company’s capital structure or its business, any merger or consolidation of the Company, any issue of stock or of options, warrants or rights to purchase stock or of bonds, debentures, preferred or prior preference stocks whose rights are superior to or affect the Common Stock or the rights thereof or which are convertible into or exchangeable for Common Stock, or the dissolution or liquidation of the Company, or any sale or transfer of all or any part of its assets or business, or any other corporate act or proceeding, whether of a similar character or otherwise.

(j) In the event of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other change affecting the Shares or the share price of the Common Stock including any Equity Restructuring, for reasons of administrative convenience, the Administrator, in its sole discretion, may refuse to permit the exercise of any Award during a period of up to thirty (30) days prior to the consummation of any such transaction.

13.3Approval of Plan by Stockholders. The Plan shall be submitted for the approval of the Company’s stockholders within twelve (12) months after the date of the Board’s initial adoption of the Plan. Awards may be granted or awarded prior to such stockholder approval; provided that such Awards shall not be exercisable, shall not vest and the restrictions thereon shall not lapse and no Shares shall be issued pursuant thereto prior to the time when the Plan is approved by the Company’s stockholders; and provided, further, that if such approval has not been obtained at the end of said twelve (12) month period, all Awards previously granted or awarded under the Plan shall thereupon be canceled and become null and void. If the Plan is not approved by the Company’s stockholders, (i) it will not become effective, (ii) no Awards shall be granted thereunder, and (iii) the Original Plan will continue in full force and effect in accordance with its terms. Upon the approval of the Plan by the Company’s stockholders, any awards outstanding under the Original Plan as of the date of such approval shall remain outstanding and, if applicable, exercisable pursuant to the terms of such individual grants.

13.4No Stockholders Rights. Except as otherwise provided herein or in an applicable Program or Award Agreement, a Holder shall have none of the rights of a stockholder with respect to Shares covered by any Award until the Holder becomes the record owner of such Shares.

13.5Paperless Administration. In the event that the Company establishes, for itself or using the services of a third party, an automated system for the documentation, granting or exercise

 


 

of Awards, such as a system using an internet website or interactive voice response, then the paperless documentation, granting or exercise of Awards by a Holder may be permitted through the use of such an automated system.

13.6Effect of Plan upon Other Compensation Plans. The adoption of the Plan shall not affect any other compensation or incentive plans in effect for the Company or any Subsidiary. Nothing in the Plan shall be construed to limit the right of the Company or any Subsidiary: (a) to establish any other forms of incentives or compensation for Employees, Directors or Consultants of the Company or any Subsidiary, or (b) to grant or assume options or other rights or awards otherwise than under the Plan in connection with any proper corporate purpose including without limitation, the grant or assumption of options in connection with the acquisition by purchase, lease, merger, consolidation or otherwise, of the business, stock or assets of any corporation, partnership, limited liability company, firm or association.

13.7Compliance with Laws. The Plan, the granting and vesting of Awards under the Plan and the issuance and delivery of Shares and the payment of money under the Plan or under Awards granted or awarded hereunder are subject to compliance with all Applicable Law (including but not limited to state, federal and foreign securities law and margin requirements), and to such approvals by any listing, regulatory or governmental authority as may, in the opinion of counsel for the Company, be necessary or advisable in connection therewith. Any securities delivered under the Plan shall be subject to such restrictions, and the person acquiring such securities shall, if requested by the Company, provide such assurances and representations to the Company as the Company may deem necessary or desirable to assure compliance with all Applicable Law. The Administrator, in its sole discretion, may take whatever actions it deems necessary or appropriate to effect compliance with Applicable Law, including, without limitation, placing legends on share certificates and issuing stop-transfer notices to agents and registrars.  Notwithstanding anything to the contrary herein, the Administrator may not take any actions hereunder, and no Awards shall be granted, that would violate Applicable Law. To the extent permitted by Applicable Law, the Plan and Awards granted or awarded hereunder shall be deemed amended to the extent necessary to conform to Applicable Law.

13.8Titles and Headings, References to Sections of the Code or Exchange Act. The titles and headings of the Sections in the Plan are for convenience of reference only and, in the event of any conflict, the text of the Plan, rather than such titles or headings, shall control. References to sections of the Code or the Exchange Act shall include any amendment or successor thereto.

13.9Governing Law. The Plan and any Programs and Award Agreements hereunder shall be administered, interpreted and enforced under the internal laws of the State of Delaware without regard to conflicts of laws thereof or of any other jurisdiction.

13.10Section 409A. To the extent that the Administrator determines that any Award granted under the Plan is subject to Section 409A, the Plan, the Program pursuant to which such Award is granted and the Award Agreement evidencing such Award shall incorporate the terms and conditions required by Section 409A. In that regard, to the extent any Award under the Plan or any other compensatory plan or arrangement of the Company or any of its Subsidiaries is subject to Section 409A, and such Award or other amount is payable on account of a Participant’s

 


 

Termination of Service (or any similarly defined term), then (a) such Award or amount shall only be paid to the extent such Termination of Service qualifies as a “separation from service” as defined in Section 409A, and (b) if such Award or amount is payable to a “specified employee” as defined in Section 409A then to the extent required in order to avoid a prohibited distribution under Section 409A, such Award or other compensatory payment shall not be payable prior to the earlier of (i) the expiration of the six-month period measured from the date of the Participant’s Termination of Service, or (ii) the date of the Participant’s death.   To the extent applicable, the Plan, the Program and any Award Agreements shall be interpreted in accordance with Section 409A. Notwithstanding any provision of the Plan to the contrary, in the event that following the Effective Date the Administrator determines that any Award may be subject to Section 409A, the Administrator may (but is not obligated to), without a Holder’s consent, adopt such amendments to the Plan and the applicable Program and Award Agreement or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, that the Administrator determines are necessary or appropriate to (A) exempt the Award from Section 409A and/or preserve the intended tax treatment of the benefits provided with respect to the Award, or (B) comply with the requirements of Section 409A and thereby avoid the application of any penalty taxes under Section 409A. The Company makes no representations or warranties as to the tax treatment of any Award under Section 409A or otherwise.  The Company shall have no obligation under this Section 13.10 or otherwise to take any action (whether or not described herein) to avoid the imposition of taxes, penalties or interest under Section 409A with respect to any Award and shall have no liability to any Holder or any other person if any Award, compensation or other benefits under the Plan are determined to constitute non-compliant, “nonqualified deferred compensation” subject to the imposition of taxes, penalties and/or interest under Section 409A.

13.11Unfunded Status of Awards. The Plan is intended to be an “unfunded” plan for incentive compensation. With respect to any payments not yet made to a Holder pursuant to an Award, nothing contained in the Plan or any Program or Award Agreement shall give the Holder any rights that are greater than those of a general creditor of the Company or any Subsidiary.

13.12Indemnification. To the extent permitted under Applicable Law and the Organizational Documents, each member of the Administrator shall be indemnified and held harmless by the Company from any loss, cost, liability, or expense that may be imposed upon or reasonably incurred by such member in connection with or resulting from any claim, action, suit, or proceeding to which he or she may be a party or in which he or she may be involved by reason of any action or failure to act pursuant to the Plan and against and from any and all amounts paid by him or her in satisfaction of judgment in such action, suit, or proceeding against him or her; provided he or she gives the Company an opportunity, at its own expense, to handle and defend the same before he or she undertakes to handle and defend it on his or her own behalf. The foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which such persons may be entitled pursuant to the Organizational Documents, as a matter of law, or otherwise, or any power that the Company may have to indemnify them or hold them harmless.

13.13Relationship to other Benefits. No payment pursuant to the Plan shall be taken into account in determining any benefits under any pension, retirement, savings, profit sharing, group insurance, welfare or other benefit plan of the Company or any Subsidiary except to the extent otherwise expressly provided in writing in such other plan or an agreement thereunder.

 


 

13.14Expenses. The expenses of administering the Plan shall be borne by the Company and its Subsidiaries.

* * * * *

I hereby certify that the foregoing Plan was duly adopted by the Board of Directors of STAAR Surgical Company on May 29, 2020.

* * * * *

I hereby certify that the foregoing Plan was approved by the stockholders of STAAR Surgical Company on July 30, 2020.

Executed on this 30th day of July 2020.

 

/s/ Samuel J. Gesten

Corporate Secretary

 

Exhibit 10.38

June 30, 2020

 

 

Dear Patrick:

 

STAAR Surgical Company is pleased to offer you the position of Chief Financial Officer reporting to Caren Mason, President and Chief Executive Officer.  Your beginning wage will be $15,192.31 per bi-weekly pay period ($395,000 annually), in addition to all the benefits offered through our current policies.

 

You will receive an initial equity grant valued at 400% of your annual base salary ($1,580,000 value) in the form of restricted share units (RSU’s). 50% of the RSU award will be time based and will vest over a three-year period: one third cliff vesting upon the first anniversary of the grant, one third cliff vesting upon the second anniversary of the grant, and one third cliff vesting upon the third anniversary of the grant.  The remaining 50% of the RSU’s awarded will be performance based and will vest according to company-based financial performance metrics. We expect STAAR’s Board of Directors will approve awarding the above-referenced RSU’s to you, effective on the first day STAAR’s trading window opens following STAAR’s disclosure of its second quarter earnings.    

 

As a participant in the Executive Long Term Incentive Plan, you will also participate in STAAR’s annual performance stock equity grants.  

 

In addition, you will participate in our Corporate Annual Incentive Bonus Program.  You will have a target bonus of 50% of your annual base salary, which will be payable on an annual basis and subject to the successful achievement of corporate and personal goals and objectives.  If the corporate bonus pool is funded for 2020 performance achievement, your prorated bonus will be calculated as to months in position and will be payable in 2021.

 

Upon achievement of your initial ninety days of employment, you will become eligible to participate in the Executive Severance and Change in Control benefit plans.  If you should experience a qualifying termination, you will receive severance pay equal to 6 months of base pay and benefits as defined under the Severance Agreement or 12 months of base pay and benefits as defined under the Change in Control Agreement.  

 

Upon acceptance of this offer and the successful completion of a background check, you may begin work.  Your expected start date will be July 6, 2020.  On your first day of employment you will need to bring identification in order to complete all necessary paperwork, including your Employment Eligibility Verification (Form I-9).  

 

Please make note, employment is at the mutual consent of the employee and STAAR and can be terminated “at will,” with or without cause, by either you or STAAR in its sole discretion at any time.

 

Patrick, we are very excited about the possibility of your joining the STAAR Executive Team.  We believe your contributions to the Company will quickly have significant and long lasting impact on STAAR.  

 

Sincerely,

 

 

 

Bill Goodmen

Vice President Global Human Resources

 

 

 

____/s/ Patrick Williams________________June 30, 2020_____________________

Patrick WilliamsDate

 

Cc:  Caren Mason


 

 

Exhibit 31.1

Certifications

I, Caren Mason, certify that:

1.I have reviewed this quarterly report on Form 10-Q of STAAR Surgical Company;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated:

 

August 5, 2020

 

/s/ CAREN MASON

 

 

 

 

Caren Mason

 

 

 

 

President, Chief Executive Officer, and Director

 

 

 

 

(principal executive officer)

 

 

 

Exhibit 31.2

Certifications

I, Patrick F. Williams, certify that:

1.I have reviewed this quarterly report on Form 10-Q of STAAR Surgical Company;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated:

 

August 5, 2020

 

/s/ PATRICK F. WILLIAMS

 

 

 

 

Patrick F. Williams

 

 

 

 

Chief Financial Officer

 

 

 

 

(principal financial officer)

 

 

 

Exhibit 32.1

Certification pursuant to 18 U.S.C. Section 1350,

As adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the filing of the Quarterly Report on Form 10-Q for the period ended July 3, 2020 (the “Report”) by STAAR Surgical Company (“Registrant”), each of the undersigned hereby certifies that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Registrant as of and for the periods presented in the Report.

 

Dated:

August 5, 2020

 

/s/ CAREN MASON

 

 

 

Caren Mason

 

 

 

President, Chief Executive Officer,

 

 

 

and Director (principal executive officer)

 

Dated:

August 5, 2020

 

/s/ PATRICK F. WILLIAMS

 

 

 

Patrick F. Williams

 

 

 

Chief Financial Officer

 

 

 

(principal financial officer)

 

A signed original of this written statement required by 18 U.S.C. Section 1350 has been provided to STAAR Surgical Company and will be furnished to the Securities and Exchange Commission or its staff upon request.